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Chapter 1
General Introduction
adapted from: Recent Research Developments 
in Microbiology. 1999, 3: 299-309
Vreugdenhil G.R., Melchers W.J.G., and Galama J.M.D.

G e n e r a l  I n t r o d u c t i o n
G ie n k e  R. V r e u g d e n h i l ,  W i l l e m  J.G. M e l c h e r s ,  a n d  J o c h e m  M.D. G a la m a .  
Department of Medical Microbiology, University of Nijmegen, Nijmegen, The Netherlands
Type I diabetes mellitus is a chronic autoimmune disease that results from the destruction of 
the insulin-producing ß-cells in the endocrine pancreas. There is strong evidence that besides 
genetic factors, environmental factors are involved in the pathogenesis of the disease. 
Increasing circumstantial evidence has linked enterovirus infections to type 1 diabetes as a 
factor either involved in the initiation and development of the disease or as a final trigger 
leading to the first clinical symptoms of diabetes. The etiologic mechanism however, has not 
been elucidated.
Type 1 diabetes mellitus
Type 1 diabetes mellitus, also known as insulin 
dependent diabetes mellitus (IDDM) is a chronic 
autoimmune disease (1), characterised by the 
inability of the body to produce insulin. Insulin is a 
hormone involved in the glucose homeostasis and it 
is produced by the -cells in the islets of Langerhans 
in the pancreas. Although symptomatic treatment is 
available, cure (by transplantation) is still not 
generally feasible. Insulin therapy usually prevents 
the acute complications, but can not completely 
prevent the development of long-term complications 
as kidney failure, proliferative retinopathy, 
cardiovascular disease and polyneuropathy. Type 1 
diabetes is the most common endocrine disorder in 
childhood and adolescence. The incidence of the 
disease increased during the last decades and 
follows a North to South gradient with the highest 
incidence observed in Scandinavian countries 
(40/100,000 per year) to a moderate incidence 
(13/100,000 per year) in the Netherlands and a 
rather low incidence (1-2/100,000 per year) in the 
south of Europe and Japan (2,3). With an increasing 
incidence rate world-wide, type I diabetes is a major 
health care problem. Insights in the aetiology of the 
disease process are mandatory to develop strategies 
to prevent the clinical outcome.
Pathology of type 1 diabetes. The pathology of 
type I diabetes is characterised by a selective
depletion of the ß-cells in the islets of Langerhans 
and the presence of large infiltrates in the pancreas 
(4). In general, the process of ß-cell destruction is 
progressive and several stages can be marked (5). A 
pre-clinical stage is characterised by insulitis and a 
specific ß-cell loss. During this stage, islet cell 
autoantibodies appear in the serum of patients. The 
destruction of ß-cells continues until a shortage in 
insulin producing capacity will become manifest as 
clinical diabetes. The clinical onset might be 
triggered by an environmental insult that leads to a 
relatively rapid ß-cell loss in a short period of time, 
and subsequently to insulin dependency. A clinical 
remission is frequently followed after insulin 
therapy, but this remission is generally of limited 
duration. In the final stage, ß-cells are completely 
lost and insulitis and autoimmunity subsides. The 
process of ß-cell destruction may take months to 
years and a residual ß-cell function may persist for 
several years (6). Onset of diabetes in very young 
children, however, illustrates that the ß-cell loss can 
very rapidly proceed.
Autoimmune processes. Autoimmune diseases 
result from an uncontrolled immune attack against 
normal tissue due to a defect in central tolerance 
induction or in the peripheral control of 
autoreactive cells. According to the orthodox 
concept of autoimmune diabetes, the loss of insulin- 
producing -cells is due to T-cell mediated 
autoimmune responses directed against the ß-cells
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(7). In adoptive transfer experiments in mice, T-cells 
indeed appeared to be the mediators of the disease, 
and it is found that induction of diabetes requires 
both CD4 and CD8 T-cells (8-10). Evidence for the 
significance of T-cells in humans is derived from 
transplantation studies. Insulitis and ß-cell 
destruction have been observed after transplantation 
of bone-marrow from diabetic patients to non­
d iabetic  rec ip ien ts  (11). Furtherm ore, 
transplantation of the pancreas from an HLA- 
identical healthy donor to a diabetes patient resulted 
in damage of the islets within the transplant and 
recurrence of diabetes (12). Finally, the progression 
of -cell damage can be prevented or delayed by 
immuno-suppressive agents (13,14). The targets of 
antigen-specific T-cells may vary from patient to 
patient and the list of candidate pancreatic 
autoantigens is increasing (15,16). The most 
important autoantigens in type 1 diabetes are 
insulin, glutamic acid decarboxylase (GAD), and 
islet cell antigen (ICA) (17).
Circulating autoantibodies directed against 
several islet cell components are a common 
characteristic in diabetic patients at onset of the 
disease and in the preclinical phase. Diabetes- 
associated autoantibodies alone, however, are not 
sufficient to mediate ß-cell destruction. This was 
demonstrated by adoptive transfer of autoantibody 
producing B lymphocytes in mice with severe 
combined immunodeficency which did not result in 
islet cell damage or glucose intolerance (18). 
Animal models have generated abundant evidence 
that -cell damage is mediated by T-cells rather than 
B cells (reviewed by 19). In addition to the orthodox 
concept of antigen-specific autoimmunity, current 
views regard non-specific immune and 
inflammatory responses to participate in mediating 
islet ß-cell destruction in type I diabetes (20). 
Cytokines and nitric oxide radicals have been 
implicated as important mediators of -cell damage 
in type 1 diabetes (21-23). Cytokines produced by 
infiltrating monocytes and NK-T-cells may play a 
role in T-cell regulation and macrophages present in 
sites of inflammation induce the production of nitric 
oxide reagents which are toxic for the ß-cells.
Aetiology. Type I diabetes is a multifactorial 
disease resulting from a complex of genetic and 
environmental factors (24,25).
Several genetics markers contribute to the 
susceptibility of type 1 diabetes. Presently, over 17 
chromosomal regions have been evaluated as 
diabetes-associated genes, one of which is the 
insulin gene (26,27). The HLA genes on 
chromosome 6 seem to encode the primary genetic 
association. The HLA-gene complex regulates the 
T-cell selection in the thymus and peptide- 
specificity of the cellular immune response (28). 
Susceptibility alleles as well as protective alleles 
may determine whether the immune system will 
either be activated or tolerised against presented 
auto-antigens (29). HLA- and non HLA-genes may 
act in concert to cause a breakdown in tolerance.
Studies in monozygotic twins revealed that 
beside genetic factors, environmental factors must 
play a role in the development of type I diabetes as 
well. The identical genetic background results in 
only a 50 % concordance rate (30). In addition, only 
about 5-10% of diabetes patients have an affected 
parent or sibling with the disease. Epidemiological 
data concerning the seasonal variation of type 1 
diabetes, epidemic-like outbreaks which are 
followed after outbreaks of viral infections, and an 
increasing incidence of type 1 diabetes world-wide, 
strongly argue for environmental factors to be 
involved. The identification of contributing factors, 
however, is difficult because of the long lag-time 
between initiation of -cell destruction and clinical 
onset of the disease. Environmental factors include 
dietary constituents, chemicals and viruses, mainly 
enteroviral infections (25).
E n t e r o v ir u s e s
Enteroviruses belong to the family of 
Picornaviridae, a family of small, non-enveloped 
RNA viruses that contain a single-stranded RNA 
genome of about 7,500 nucleotides (31). The genus 
enterovirus consists of 66 serotypes sub-grouped in 
poliovirus (PV), coxsackie A and B viruses (CVA 
and CVB), ECHO viruses, and the numbered 
enteroviruses. According to their molecular 
structure the enteroviruses can be divided into two 
major groups: a PV-like and a CVB-like group. The 
CVB-like group consists of the CVB types 1-6, 
some CVA (type 9, 16) and the majority of ECHO 
viruses.
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Enterovirus lifecycle. Enteroviruses have a lytic 
infectious cycle. Cell entry takes place via 
attachment to specific cell surface receptors, of 
which presently only few are known (32). Once 
taken up, the virus will be uncoated, and translation 
of viral proteins starts via a cap-independent 
initiation of translation. The viral RNA directs the 
synthesis of a single polyprotein, which is auto- 
proteolytically cleaved into the different capsid and 
non-structural proteins. The polyprotein contains 
three regions: P1, P2 and P3. The P1 region encodes 
the four capsid proteins (VP4, VP2, VP3, and VP1) 
which form the icosahedral capsid of the virus. The 
P2 region encodes three non-structural proteins (2A, 
2B, and 2C), and the P3 region encodes the non- 
structural proteins 3A, 3B, 3C, and 3D. Most non- 
structural proteins are also present as functional 
precursors, all are involved in the translation and 
replication of the virus. The mechanism of virus 
encapsidation and release from the cell are largely 
unknown. The virus induces dramatic metabolic and 
morphologic changes in the host cell. The most 
prominent changes are an accumulation of 
membranous vesicles in the cytoplasma and a 
specific inhibition of host cell translation (33,34). 
Collectively, the biochemical and structural 
alterations are known as the cytopathic effect, 
finally resulting in lysis of the cell.
clinical manifestation of enteroviral infections.
Enteroviruses are common human pathogens that 
can cause a spectrum of diseases, but infections are 
usually mild. Enteroviral infections may follow a bi- 
phasic course, with a secondary viraemia and 
dissemination of the infection to target organs such 
as heart, brains, pancreas, or muscle which 
incidentally lead to a severe course of the disease 
with for instance paralysis, meningo-encephalitis, 
and myocarditis (35). Chronic inflammatory 
diseases like polymyositis, chronic myocarditis and 
type 1 diabetes mellitus have also been associated 
with enteroviral infections. A considerable overlap 
exists among the enteroviral serotypes and the 
symptoms they induce. The pathogenesis depends 
on genetic characteristics of the virus as well as 
multiple host-related factors including age, gender, 
nutritional status, genetic constitution and immune 
status (35).
Host immune response. Antibody responses are 
pivotal in the defence against enteroviruses for they 
are responsible for clearance of the infection (36). 
The neutralising antibodies are directed against the 
capsid surface of the virus and are virus type 
specific. Enterovirus IgG antibodies persist for 
years and boosting may result from either a 
homologous (same serotype) or a heterologous 
(different enterovirus) response. Besides antibody 
responses, T lymphocytes are also activated during 
an enteroviral infection. T helper epitopes have 
been identified in the capsid of the virus (37-39). 
Recently, it was shown that, despite the lytic 
lifecycle and rapid induction of cytopathic effects, 
enteroviruses are capable of inducing strong 
cytotoxic T-cell responses (40).
E n t e r o v ir u s e s  a n d  t y p e  I d ia b e t e s
The association of enteroviruses with type 1 
diabetes has been extensively studied. The primary 
basis for an association of enteroviruses with the 
development of diabetes was the isolation of a 
CVB4 virus from the pancreas of a child who died 
from diabetic ketoacidose after acute onset of 
diabetes (41). The isolated virus was capable of 
inducing hyperglycaemia in mice, thereby fulfilling 
Koch’s postulate. During the following years more 
cases were reported in which the isolation of CVB 
after acute onset of diabetes was described 
(reviewed by 42). Additional indications for a role 
of enteroviruses came from epidemiological studies, 
which showed epidemic-like raises in incidence of 
type 1 diabetes after outbreaks of enterovirus 
infections (43,44). Furthermore, immunological 
studies have shown that both humoral and cellular 
immune reactivity directed against CVB are 
elevated in patients at onset of type 1 diabetes, 
when compared to matched controls (42,45-48). 
Case control studies indicated that even intrauterine 
exposure to enteroviruses is a risk factor for 
childhood onset of diabetes (49). The most 
convincing indications however, are supplied by 
prospective follow up studies where it appeared that 
patients who acquired type 1 diabetes had a higher 
rate of enteroviral infections in the years before 
onset of the disease as compared to non-affected 
siblings or unrelated controls (50,51). In some
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cases, the conversion for autoantibodies against islet 
cells was temporaly associated with recent 
enterovirus infections (52) which suggests that virus 
infections play a role in the initiation of 
autoimmunity. Whereas the association with 
diabetes was initially ascribed to CVB4, other CVB, 
some CVA, and several ECHO viruses are 
associated with the disease as well (51).
I n v o l v e m e n t  o f  e n t e r o v ir u s e s  in  t h e  
p a t h o g e n e s is  o f  t y p e  I d ia b e t e s .
Several possible mechanisms for a role of CVB 
infections in the development of type 1 diabetes 
have been suggested (53-56). The models describe 
either direct pathogenic effects of the virus on the ß- 
cells (model 1), their putative role in induction of 
autoimmunity to GAD65 (model 2), and their role in 
immune modulation and contribution to bystander 
processes (model 3).
model 1: ß-cell infection by enteroviruses. The
isolation of a virus from the pancreas of a child with 
acute onset of diabetes suggested that, at least in 
acute cases (which are rather a-typical), the virus 
can mediate destruction of the pancreatic ß-cells 
(41,57). Beta-cell destruction may thus result either 
from the lytic effects of the virus infection or from a 
virus-directed immune responses against virus- 
infected ß-cells (Fig. 1). It has been reported that 
about 30% of the CVB4 strains have a tropism for 
the murine pancreas (58) and other types of 
enteroviruses (CVA7, CVA9, CVB5) are able to 
destroy mouse ß-cells in vitro as well (59) However, 
the mouse is not a natural host for enteroviruses. 
Human studies are needed to confirm putative 
cytopathic effects of the virus to human ß-cells.
model 2: Molecular mimicry. The model of 
molecular mimicry is a long-standing hypothesis 
that represents the concept that micro-organisms 
such as bacteria and viruses can initiate and/or 
sustain anti-self immune responses (53,60,61). The 
model is based on a sequence homology between a 
microbial protein and a host cellular protein. In 
1992, a sequence homology between the cellular 
protein glutamic acid decarboxylase (GAD65) and the 
CVB4 viral protein p2C was described
Figure 1. Schematic view of the immune response induced by a 
viral infection in the pancreatic ß-cells. Infected cells display 
processed viral antigens by means of their HLA class I 
molecules to the antigen receptor of CD8+ T-cells. The activated 
T-cells can kill infected ß-cells. Macrophages (infected or 
having phagocytosed virions) present the viral peptides to CD4+ 
T-cells, which by their cytokine production help B lymphocytes 
to produce antiviral antibodies and anti- -cell autoantibodies. 
Adapted from (53 ).
comprising a stretch of 6 identical amino acids with 
close sequence similarity (Fig. 2) (62,63).
The process of molecular mimicry starts with an 
immune response to virally infected cells and 
antigen-presenting cells, which display viral 
proteins by means of their HLA class I and class II 
molecules. CD4+ and CD8+ T lymphocytes will be 
activated and subsequently direct their effector 
functions to cells expressing the mimicry peptide.
g a d 65 250
CVB4-p2C 28
A m M  1 a r  f K M F P E V K E K g m a a L P R L
If  I j E j W L K V K I L P E V K E K H E IF - L S R L
I A 
K Q
Figure 2. Sequence homology between GAD65 and CVB4 
protein 2C. Solid lines enclose identical amino acid residues. 
Dashed lines enclose amino acids with similar polarity, 
hydrophobicity or charge. Numbers refer to the number of 
amino acid residues from the amino terminus of each protein.
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According to this model, infection by CVB would 
result in activation of p2C-specific T-cells, that 
cross-react with GAD65 expressed on ß-cells (64) 
(Fig. 3).
GAD65 is a major antigen in type 1 diabetes mellitus 
and GAD65 antibodies have a predictive value for 
progression to diabetes (65,66). From a prospective 
cohort study in Finland, it appeared that in some 
patients who developed diabetes, infection with 
enterovirus co-incided with the appearance of 
autoantibodies in the serum against islet cell antigen 
(ICA) and GAD65, which is a component of ICA 
(52). These data indeed suggest that enteroviruses 
trigger autoimmunity against GAD65.
model 3: selective bystander killing o f ß-cells
A local virus infection provides alarm signals, 
necessary to activate and potentiate an efficient 
cellular immune response (67). Besides the 
regulation of HLA expression and expression of co­
stimulation and adhesion molecules, this results in 
the production of a high level of locally produced 
chemokines and cytokines (68) (Fig. 4). Pro- 
inflammatory cytokines produced during 
inflammation in the pancreas can cause initial -cell 
damage (21). Furthermore, these cytokines may 
modulate the immune response and might be 
involved in bystander activation of potentially 
autoreactive T-cells (23). A shift of the cytokine 
balance from a Th2 to a Th1-like response directs 
the immune response towards cellular autoimmunity 
and influences the progression rate of the disease 
(69), whereas Th2 cytokines activate B lymphocytes 
toproduce antibodies and keep the autoimmune 
responses in a less progressive state. It is not known 
whether enteroviruses may modulate the immune 
response in diabetes patients. More insight in the 
role of pathogens in modulation of the immune 
response may help to device strategies to delay or 
even prevent onset of type 1 diabetes mellitus.
A i m  a n d  o u t l in e  o f  t h e  T h e s is
The objective of the studies described in this thesis 
was to obtain insights in the pathophysiologic 
contribution of enteroviruses to the induction and 
development of type 1 diabetes mellitus. The
Figure 3. Schematic view of the molecular mimicry model. The 
process of autoimmunity begins with an immune response to a 
cell (not a -cell) infected with an unknown vius, the proteins of 
which share amino acid sequence with a -cell protein. The 
infected cells display processed viral antigens to the antigen 
receptors of T-cells by means of their MHC molecules. The 
activatd T-cells become effector cells that can kill beta cells 
expressing a peptide common to them and the viral protein. 
Macrophages (infected or having phagocytosed virions) present 
the viral peptides to CD4+ T-cells which by their cytokine 
production help B lymphocytes to produce autoantibodies. 
Adapted from (53).
putative pathogenic mechanisms which are 
investigated included direct mechanisms by 
infection of the pancreatic ß-cells, and indirect 
mechanisms as molecular mimicry and bystander 
effect through cytokines. Aspects of the hypothesis 
of molecular mimicry are investigated in chapter 2 
and 3. Chapter 2 focusses on the role of HLA alleles 
in cross-reactive T-cell responses against the viral 
protein 2C and the islet antigen GAD65. In chapter
3, antibody responses against CVB and the viral 
protein 2C are analysed and a possible antibody 
cross-reactivity with GAD65 is discussed. In chapter
4, the pathologic mechanism of enterovirus-induced 
type 1 diabetes was investigated in a child who 
acutely developed insulin dependency after a severe 
Echo 9 virus infection. The lack of evidence for a 
pancreatic infection suggested indirect mechanisms
15
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Figure 4. Model for the bystander killing of pancreatic ß- cell 
damage. A local viral infection result in to the production of 
cytokines. Macrophages, activated by viral antigens, produce 
pro-inflamatory cytokines and nitric oxide which are toxic for 
the - cell. Infected cells display viral antigens to CD4+ T 
lymphocytes. The activated T-cells produce cytokines of the 
Th1 phenotype in order to help cytotoxic T-cells to kill infected 
cells. Bystander activation of local existing T-cells may take 
place through the release of cytokines.
to  contribute to  the d evelopm en t o f  type 1 diabetes  
in  th is child . In chapter 5, the e ffec t o f  C V B  on  
leu co cy te  cytok ine production  is  investigated . 
Chapter 6 reports the induction  o f  -ce ll to x ic  
cytok ine T N F -a  b y  the ß -ce ll- assoc ia ted  pancreatic  
ductal ce lls  upon in fection  w ith  C V B . F inally , in  
chapter 7, a sum m ary o f  the stud ies are g iven  and 
the aetio lo g ic  role o f  enteroviruses in  typ e 1 
diabetes m ellitu s is d iscu ssed .
R e f e r e n c e s
1. Eisenbarth, G. S. 1986. Type I diabetes mellitus. A 
chronic autoimmune disease. N. Engl. J. Med. 314:1360.
2. Green, A., E. A. Gale, and C. C. Patterson. 1992. 
Incidence of childhood-onset insulin-dependent diabetes 
mellitus: the EURODIAB ACE Study. Lancet 339.905.
3. Ruwaard, D., R. A. Hirasing, H. M. Reeser, S. van 
Buuren, K. Bakker, R. J. Heine, R. A. Geerdink, G. J. 
Bruining, G. J. Vaandrager, and S. P. Verloove 
vanhorick. 1994. Increasing incidence of type I diabetes 
in The Netherlands. The second nationwide study among 
children under 20 years of age. Diabetes Care 17:599.
4. Gepts, W. 1965. Pathologic anatomy of the pancreas in
juvenile diabetes mellitus. Diabetes 14:619.
5. Connor, E. and N. K. Maclaren. 1993. Towards 
prevention of insulin-dependent diabetes mellitus. In 
Causes of Diabetes: Genetic and environmental factors. R.
D. G. Leslie, editor. John Wiley & Sons Ltd. Ontario. 141­
153.
6. Rahier, J. 1988. The diabetic pancreas: a pathologist's 
view. In The pathology of the endocrine pancreas in 
diabetes. P. Lefebvre and D. Pipeleers, editors. Springer­
Verlag, Berlin. 17-40.
7. Bach, J. F. 1994. Insulin-dependent diabetes mellitus as 
an autoimmune disease. Endocr. Rev. 15:516.
8. Bendelac, A., C. Carnaud, C. Boitard, and J. F. Bach. 
1987. Syngeneic transfer of autoimmune diabetes from 
diabetic NOD mice to healthy neonates. Requirement for 
both L3T4+ and Lyt-2+ T-cells. J. Exp. Med. 166:823.
9. Wicker, L. s., B. J. Miller, and Y. Mullen. 1986. 
Transfer of autoimmune diabetes mellitus with splenocytes 
from nonobese diabetic (NOD) mice. Diabetes 35:855.
10. Yagi, H., M. Matsumoto, K. Kunimoto, J. Kawaguchi,
S. Makino, and M. Harada. 1992. Analysis of the roles of 
CD4+ and CD8+ T cells in autoimmune diabetes of NOD 
mice using transfer to NOD athymic nude mice. Eur. J. 
Immunol. 22:2387.
11. Lampeter, E. F., M. Homberg, K. Quabeck, U. W. 
Schaefer, P. Wernet, J. Bertrams, H. Grosse Wilde, F.
A. Gries, and H. Kolb. 1993. Transfer of insulin­
dependent diabetes between HLA-identical siblings by 
bone marrow transplantation. Lancet 341:1243.
12. Sibley, R., D. E. R. Sutherland, F. Goetz, and A. F. 
Michael. 1985. Recurrent diabetes mellitus in pancreas 
iso-and allograft: a light and electron microscopic and 
immunohistochemical analysis of four cases. Lab Invest 
53:132.
13. Stiller, C. R., J. Dupre, M. Gent, M. R. Jenner, P. A. 
Keown, A. Laupacis, R. Martell, N. W. Rodger, B. von 
Graffenried, and B. M. Wolfe. 1984. Effects of 
cyclosporine immunosuppression in insulin-dependent 
diabetes mellitus of recent onset. Science 223:1362.
14. Bougneres, P. F., J. C. Carel, L. Castano, C. Boitard, J. 
P. Gardin, P. Landais, J. Hors, M. J. Mihatsch, M. 
Paillard, J. L. Chaussain, and et al. 1988. Factors 
associated with early remission of type I diabetes in 
children treated with cyclosporine. N. Engl. J. Med. 
318:663.
15. Green, I. C., J. M. Cunningham, C. A. Delaney, M. R. 
Elphick, J. G. Mabley, and M. H. Green. 1994. Effects 
of cytokines and nitric oxide donors on insulin secretion, 
cyclic GMP and DNA damage: relation to nitric oxide 
production. Biochem. Soc. Trans. 22:30.
16. Roep, B. O. 1996. T cell responses to autoantigens in 
IDDM: The search for the holy grail. Diabetes 45:1147.
17. Tisch, R. and H. McDevitt. 1996. Insulin-dependent 
diabetes mellitus. Cell 85:291.
18. Petersen, J. S., M. O. Marshall, S. Baekkeskov, K. R. 
Hejnaes, M. Hoier Madsen, and T. Dyrberg. 1993. 
Transfer of type 1 (insulin-dependent) diabetes mellitus 
associated autoimmunity to mice with severe combined 
immunodeficiency (SCID). Diabetologia 36:510.
16
General Introduction
19. Rossini, A. A., D. L. Greiner, H. P. Friedman, et al.
1993. Immunopathogenesis of diabetes mellitus. Diabetes 
Rev 1:43.
20. Kolb, H., V. Kolb Bachofen, and B. O. Roep. 1995. 
Autoimmune versus inflammatory type I diabetes: a 
controversy? Immunol. Today 16:170.
21. Mandrup Poulsen, T. 1996. The role of interleukin-1 in 
the pathogenesis of IDDM. Diabetologia 39:1005.
22. Corbett, J. A. and M. L. McDaniel. 1992. Does nitric 
oxide mediate autoimmune destruction of beta-cells? 
Possible therapeutic interventions in IDDM. Diabetes 
41:897.
23. Rabinovitch, A. 1994. Immunoregulatory and cytokine 
imbalances in the pathogenesis of IDDM. Therapeutic 
interention by immunostimulation? Diabetes 43:613.
24. Champsaur, H. F., G. F. Bottazzo, J. Bertrams, R. 
Assan, and C. Bach. 1982. Virologic, immunologic, and 
genetic factors in insulin-dependent diabetes mellitus. J. 
Pediatr. 100.15.
25. Castano, L. and G. S. Eisenbarth. 1990. Type-I diabetes: 
a chronic autoimmune disease of human, mouse, and rat. 
Annu. Rev. Immunol. 8:647
26. Rich, S. S. 1995. Positional cloning works! Identification 
of genes that cause IDDM. Diabetes 44:139.
27. Dorman, J. S., R. E. LaPorte, and M. Trucco. 1991. 
Genetics of diabetes. Genes and environment. Baillieres. 
Clin. Endocrinol. Metab. 5:229.
28. Nepom, G. T. 1990. A unified hypothesis for the complex 
genetics of HLA associations with IDDM. Diabetes 
39.1153.
29. Wicker, L. S. 1997. Major histocompatibility complex- 
linked control of autoimmunity. J. Exp. Med. 186:973.
30. Tattersall, R. B. and D. A. Pyke. 1972. Diabetes in 
identical twins. Lancet 2:1120.
31. Wimmer, E., C. U. Hellen, and X. Cao. 1993. Genetics of 
poliovirus. Annu. Rev. Genet. 27:353
32. Selinka, H  C., M. Huber, A. Pasch, K. Klingel, C. 
Aepinus, and R. Kandolf. 1998. Coxsackie B virus and its 
interaction with permissive host cells. Clinical and 
Diagnostic Virology 9:115.
33. van Kuppeveld, F. J., J. G. Hoenderop, R. L. Smeets, P. 
H  Willems, H  B. Dijkman, J. M. Galama, and W. J. 
Melchers. 1997. Coxsackievirus protein 2B modifies 
endoplasmic reticulum membrane and plasma membrane 
permeability and facilitates virus release. EMBO J. 
16:3519.
34. Zoll, G. J., J. M. D. Galama, and W. J. G. Melchers.
1998. Translational control in picornavirus infected cells. 
In Recent research developments in microbiology. S. G. 
Pandalai, editor. Research Signpost, Trivandrum. 319-333.
35. Melnick, J. L. 1985. Enteroviruses: Polioviruses, 
coxsackieviruses, echoviruses and newer enteroviruses. In 
Virology. B. N. Fields, editor. Raven Press, New York. 
739-794.
36. Galama, J. M. D. 1997. Enteroviral infections in the 
immunocompromised host. Rev Med Microbiol 8:33.
37. Graham, S., E. C. Wang, O. Jenkins, and L. K. 
Borysiewicz. 1993. Analysis of the human T-cell response 
to picornaviruses: identification of T-cell epitopes close to 
B-cell epitopes in poliovirus. J. Virol. 67:1627.
38. Mahon, B. P., K  Katrak, A. Nomo to, A. J. Macadam, 
P. D. Minor, and K. H  Mills. 1995. Poliovirus-specific 
CD4+ Th1 clones with both cytotoxic and helper activity 
mediate protective humoral immunity against a lethal 
poliovirus infection in transgenic mice expressing the 
human poliovirus receptor. J. Exp. Med. 181:1285.
39. Kutubuddin, M., J. Simons, and M. Chow. 1992. 
Identification of T-helper epitopes in the VP1 capsid 
protein of poliovirus. J. Virol. 66:3042.
40. Mandl, S., L. J. Sigal, K. L. Rock, and R. Andino. 1998. 
Poliovirus vaccine vectors elicit antigen-specific cytotoxic 
T cells and protect mice against lethal challenge with 
malignant melanoma cells expressing a model antigen. 
Proc. Natl. Acad. Sci. U. S. A. 95:8216.
41. Yoon, J. W., M. Austin, T. Onodera, and A. L. Notkins. 
1979. Isolation of a virus from the pancreas of a child with 
diabetic ketoacidosis. N. Engl. J. Med. 300.1173.
42. Szopa, T. M., P. A. Titchener, N. D. Portwood, and K. 
W. Taylor. 1993. Diabetes mellitus due to viruses--some 
recent developments. Diabetologia 36:687.
43. Fohlman, J. and G. Friman. 1993. Is juvenile diabetes a 
viral disease? Ann. Med. 25:569.
44. Gamble, D. R. and K  W. Taylor. 1969. Seasonal 
incidence of diabetes mellitus. Br. Med. J. 3:631.
45. Gamble, D. R., M. L. Kinsley, M. G. FitzGerald, R. 
Bolton, and K. W. Taylor. 1969. Viral antibodies in 
diabetes mellitus. Br. Med. J. 3:627.
46. Frisk, G., E. Nilsson, T. Tuvemo, G. Friman, and H  
Diderholm. 1992. The possible role of Coxsackie A and 
echo viruses in the pathogenesis of type I diabetes mellitus 
studied by IgM analysis. J. Infect. 24:13.
47. Juhela, S., H. Hyoty, M. Lonnrot, M. Roivainen, O. 
Simell, and J. Ilonen. 1998. Enterovirus infections and 
enterovirus specific T-cell responses in infancy. J. Med. 
Virol. 54:226.
48. Banatvala, J. E., J. Bryant, G. Schernthaner, M. 
Borkenstein, E. Schober, D. Brown, L.M. De Silva, 
M.A. Menser, and M, Silink. 1985. Coxsackie B, mumps, 
rubella, and cytomegalovirus specific IgM responses in 
patients with juvenile-onset insulin-dependent diabetes 
mellitus in Britain, Austria, and Australia. Lancet 1:1409.
49. Dahlquist, G., G. Frisk, S. A. Ivarsson, L. Svanberg, M. 
Forsgren, and H  Diderholm. 1995. Indications that 
maternal coxsackie B virus infection during pregnancy is a 
risk factor for childhood-onset IDDM. Diabetologia 
38:1371.
50. Hyoty, H., M. Hiltunen, M. Knip, M. Laakkonen, P. 
Vahasalo, J. Karjalainen, P. Koskela, M. Roivainen, P. 
Leinikki, T. Hovi, et al. 1995. A prospective study of the 
role of coxsackie B and other enterovirus infections in the 
pathogenesis of IDDM. Childhood Diabetes in Finland 
(DiMe) Study Group. Diabetes 44:652.
51. Roivainen, M., M. Knip, H  Hyoty, P. Kulmala, M. 
Hiltunen, P. Vahasalo, T. Hovi, and H  K  Akerblom. 
1998. Several different enterovirus serotypes can be 
associated with prediabetic autoimmune episodes and 
onset of overt IDDM. J. Med. Virol. 56:74.
52. Hiltunen, M., H  Hyoty, M. Knip, J. Ilonen, H  
Reijonen, P. Vahasalo, M. Roivainen, M. Lonnrot, P. 
Leinikki, T. Hovi, and H  K. Akerblom. 1997. Islet cell
17
Chapter 1
antibody seroconversion in children is temporally 
associated with enterovirus infections. Childhood Diabetes 
in Finland (DiMe) Study Group. J. Infect. Dis. 175:554.
53. Atkinson,M.A., and N. K. Maclaren. 1994. The 
pathogenesis of insulin-dependent diabetes mellitus. N. 
Eng. J. Med. 331:1428.
54. von Herrath, M. G., A. Holz, D. Homann, and M. B. 
oldstone. 1998. Role of viruses in type I diabetes. Semin. 
Immunol. 10.87.
55. Zinkernagel, R. M., S. Cooper, J. Chambers, R. A. 
Lazzarini, H  Hengartner, and H. Arnheiter. 1990. 
Virus-induced autoantibody response to a transgenic viral 
antigen. Nature 345:68.
56. Yoon, J. W. 1991. Role of viruses in the pathogenesis of 
IDDM. Ann. Med. 23:437.
57. Jenson, A. B., H  S. Rosenberg, and A. L. Notkins. 1980. 
Pancreatic islet-cell damage in children with fatal viral 
infections. Lancet 2:354.
58. Szopa, T. M., T. Ward, D. M. Dronfield, N. D. 
Portwood, and K. W. Taylor. 1990. Coxsackie B4 viruses 
with the potential to damage beta cells of the islets are 
present in clinical isolates. Diabetologia 33:325.
59. Bopegamage, S. A. and A. Petrovicova. 1994. In vitro 
infection of mouse pancreatic islet cells with coxsackie 
viruses. Acta Virol. 38:251.
60. Oldstone, M. B., M. Nerenberg, P. Southern, J. Price, 
and H. Lewicki. 1991. Virus infection triggers insulin­
dependent diabetes mellitus in a transgenic model: role of 
anti-self (virus) immune response. Cell 65:319.
61. Wucherpfennig, K. W. and J. L. Strominger. 1995. 
Molecular mimicry in T cell-mediated autoimmunity: viral 
peptides activate human T cell clones specific for myelin 
basic protein. Cell 80.695.
62. Kaufman, D. L., M. Clare Salzler, J. Tian, T. 
Forsthuber, G. S. Ting, P. Robinson, M. A. Atkinson, E.
E. Sercarz, A. J. Tobin, and P. V. Lehmann. 1993. 
Spontaneous loss of T-cell tolerance to glutamic acid
decarboxylase in murine insulin-dependent diabetes. 
Nature 366:69.
63. Kaufman, D. L., M. G. Erlander, M. Clare Salzler, M.
A. Atkinson, N. K. Maclaren, and A. J. Tobin. 1992. 
Autoimmunity to two forms of glutamate decarboxylase in 
insulin-dependent diabetes mellitus. J. Clin. Invest. 
89.283.
64. Atkinson, M. A., M. A. Bowman, L. Campbell, B. L. 
Darrow, D. L. Kaufman, and N. K. Maclaren. 1994. 
Cellular immunity to a determinant common to glutamate 
decarboxylase and coxsackie virus in insulin-dependent 
diabetes. J. Clin. Invest. 94:2125.
65. Baekkeskov, S., H. J. Aanstoot, S. Christgau, A. Reetz, 
M. Solimena, M. Cascalho, F. Folli, H. Richter olesen, 
P. DeCamilli, and P. D. DeCamilli. 1990. Identification
o f  
the 64K autoantigen in insulin-dependent diabetes as the 
GABA-synthesizing enzyme glutamic acid decarboxylase. 
Nature 347:151.
66. Ellis, T. M. and M. A. Atkinson. 1996. The clinical 
significance of an autoimmune response against glutamic 
acid decarboxylase. Nat. Med. 2:148.
67. Pennisi, E. 1996. Teetering on the brink of danger. 
S c i e n c e  
271:1665.
68. Ohashi, P. S., S. Oehen, P. Aichele, H  Pircher, B. 
odermatt, P. Herrera, Y. Higuchi, K. Buerki, H. 
Hengartner, and R. M. Zinkernagel. 1993. Induction of 
diabetes is influenced by the infectious virus and local 
expression of MHC class I and tumor necrosis factor­
alpha. J. Immunol. 150.5185
69. Trembleau, S., G. Penna, E. Bosi, A. Mortara, M. K. 
Gately, and L. Adorini. 1995. Interleukin 12 
administration induces T helper type 1 cells and 
accelerates autoimmune diabetes in NOD mice. J. Exp. 
Med. 81:817.
18
Chapter 2
Molecular mimicry in diabetes mellitus: 
the homologous domain in coxsackie B virus 
protein 2C and islet autoantigen GAD65 is highly 
conserved in the coxsackie B-like enteroviruses 
and binds to the diabetes associated HLA-DR3 molecule.
Diabetologia. 1998, 41: 40-46
Vreugdenhil G.R., Geluk A., Ottenhoff T.H.M. 
Melchers W.J.G., Roep B.O., and Galama J.M.D.

Molecular mimicry in diabetes: the homologous domain in coxsackie B virus 
protein 2C and islet autoantigen GAD65 is highly conserved in the coxsackie 
B-like enteroviruses and binds to the diabetes associated HLA-DR3 molecule.
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It has been proposed that molecular mimicry between protein 2C (p2C) of coxsackie 
virus B4 and the autoantigen glutamate decarboxylase (GAD65) plays a role in the 
pathogenesis of insulin dependent diabetes mellitus (IDDM). In this study we show that 
the amino acid sequence of p2C which shares homology with a sequence in GAD65 
(PEVKEK), is highly conserved in coxsackie virus B4 isolates as well as in different 
viruses of the subgroup of coxsackie B-like enteroviruses. These are the most prevalent 
enteroviruses and therefore exposure to the mimicry motif will be a frequent event 
throughout life. Presentation of the homologous peptides by HLA molecules is essential 
for T-cell reactivity. Therefore, we tested whether the PEVKEK motif can bind to the 
IDDM-associated HLA-DR1, -DR3 and -DR4 molecules. Synthetic peptides with 
sequences derived from p2C and GAD65 did bind to HLA-DR3 but not to HLA-DR1 or - 
DR4. Replacement of amino acids within the motif showed that the PEVKEK motif binds 
specifically to HLA-DR3. Moreover, both, p2C and GAD65 peptides bind in the same 
position within the peptide binding groove of the DR3 molecule which is an essential 
requirement for T-cell cross-reactivity. The results support molecular mimicry between 
p2C of coxsackie B-like enteroviruses and GAD65. However, this molecular mimicry may 
be limited to the HLA-DR3 positive Subpopulation of the IDDM patients.
Despite a growing knowledge of insulin-dependent 
diabetes mellitus (IDDM), its aetiology is still 
obscure. Both, genetic and environmental factors 
are involved, and autoimmune mechanisms play a 
crucial role in the pathogenesis (1,2). Studies in 
transgenic mice have renewed interest in the 
potential role of viruses in causing autoimmunity in 
diabetes (3,4). Strong candidates are the 
enteroviruses, particularly the coxsackie B viruses 
(CVB). The association of these viruses with IDDM 
is based on isolation of CVB from the pancreas in 
fatal cases of diabetes (5,6) and on epidemiological 
studies that showed an increased incidence of 
IDDM after epidemics caused by enteroviruses
(7,8). It has also been reported that antibodies to 
CVB are more prevalent in patients at onset of 
IDDM, as compared to matched control subjects 
(9,10). Serological case control studies indicated 
intrauterine exposure to enteroviruses to be a risk 
factor for childhood onset of IDDM (11,12). 
Furthermore, it has been shown that patients who 
acquired IDDM had a higher rate of enteroviral 
infections in the years before onset of the disease as 
compared to non-affected siblings or unrelated 
control subjects (12).
The mechanism by which enteroviruses may 
contribute to destruction of pancreatic ß-cells 
remains to be established. The virus may destruct ß-
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cells either directly by a lytic infection, or indirectly 
by a virus-directed immune response against 
infected ß-cells (13). Beta cells may also 
specifically be damaged by nitric oxide radicals and 
cytokines that are produced as a consequence of 
viral infection and subsequent inflammation, a 
process of so called “innocent bystander killing”
(14). Alternatively, a mechanism, called molecular 
mimicry, may play a role in induction of 
autoimmunity, ultimately leading to destruction of 
pancreatic beta cells (15). Molecular mimicry is 
based on a sequence homology between a foreign 
antigen, e.g. a viral protein, and a host protein. It is 
postulated that immune reactivity against the virus 
can lead to a cross-reactive response to the 
homologous sequence of the host protein (3,4,15). 
In the concept of molecular mimicry both genetic 
factors such as HLA association, and viruses as 
environmental factors, are integrated in a single 
aetiologic concept.
In 1992 it was reported that a homology exists 
between the 65kDa isoform of glutamic acid 
decarboxylase (GAD65) and p2C, a non-structural 
protein of CVB4 (16,17). A complete homology was 
reported for 10 amino acids, and similarity for 9 
residues. GAD65 is mainly expressed in the pancreas 
and central nervous system (18), and is a dominant 
autoantigen that has a predictive value for 
progression to IDDM (16,17,19). Autoantibodies 
against GAD65 precede the onset of diabetes and are 
found in up to 80% of newly diagnosed patients, but 
rarely in healthy control subjects (19,20). In a study 
on antibody reactivity to GAD65 and to synthetic 
p2C peptides, evidence was obtained in support of a 
cross-reactive antibody response (21). In two other 
studies, however, cross-reactivity could not be 
demonstrated (22,23). T-cell responses to GAD65 
peptides that share homology with p2C, were found 
in newly diagnosed diabetes patients (24) but also in 
healthy unrelated control subjects (25). In one of 
these studies, T-cell reactivity was also found 
against the corresponding p2C peptides (24). Formal 
evidence for T-cell cross-reactivity was not 
obtained, however, because the studies were 
performed with bulk cultures of PBMC and not with 
T-cell clones (24). Cross-reactivity between GAD65 
and p2C has furthermore been demonstrated in the 
non-obese diabetes (NOD) mouse where it appeared 
to be linked with a MHC allele that is associated
with susceptibility for diabetes (26). Presentation of 
the mimicry motif by MHC molecules is an essential 
requirement for T-cell cross-reactivity. In humans, 
binding of the mimicry motif to HLA molecules that 
are associated with IDDM, has not been reported so 
far.
Enteroviruses are RNA viruses which replicate 
with a high mutation rate (27) and show a 
considerable genetic variation (28). As a 
consequence, the mimicry motif might be found 
only in a few isolates, thus restraining the frequency 
of exposure to this sequence. To address this 
question we analysed conservation of the mimicry 
sequence among different CVB-like enteroviruses. 
Based on the sequences that were obtained, binding 
of the viral peptides as well as the GAD65 peptide 
was studied to HLA-DR1, -DR3, and -DR4 alleles, 
which are associated with IDDM.
m a t e r i a l s  a n d  m e t h o d s
V irus isolates. Ten Coxsackie B4 virus strains, isolated 
in the Netherlands between 1974 and 1990 were obtained 
from the National Institute o f  Public Health and 
Environmental Protection, Bilthoven (RIVM), The 
Netherlands. Another 11 enteroviruses o f  different strains 
were isolated in the Academic Hospital Nijmegen  
between 1981 and 1994 and were routinely serotyped 
with a set o f  typing sera from the RIVM (29). The 
enteroviruses were subdivided into the group o f  polio-like 
(PV-like) viruses and CVB-like viruses as classified by 
Hyypiä et al. (30). The clinical isolates belonged to the 
CVB-like group, including 3 CVB1 isolates, 2 CVB2, 2 
CVB3, 1 CV b5, 3 CVA9, and 1 echovirus 9 isolate. The 
isolates were randomly selected. The echovirus 9 isolate 
was obtained from a patient with clinical symptoms o f  
IDDM.
Reverse transcription-polym erase chain reaction  
(RT-PCR) and sequence analysis. Viruses were 
propagated in Buffalo Green Monkey kidney cells 
(b Gm ). After complete cytopathic effect was reached the 
cultures were frozen and thawed three times. RNA was 
extracted by using a single extraction procedure with 
guanidinium thiocyanate-phenol-chloroform according to 
the method o f  Chomczynski & Sacchi (31). Reverse 
transcriptase reactions and PCR were performed as 
previously described (32). Briefly, cD N A  was 
synthesised in a 20 ^l reaction mixture containing 75 
mmol/l KCl, 50 mmol/l Tris-HCl pH 8.3, 3 mmol/l 
M gCl2, 10 mmol/l DTT, 0.2 m m ol/l o f  each  
deoxynucleoside triphosphate (Boehringer Mannheim, 
Mannheim, Germany), 50 pmol o f  the degenerated 
antisense primer (5'TCG TCT CCG TGG CGA TGG
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CTN A A N  CA 3'), 5 units o f  avian myeloblastosis virus 
reverse transcriptase (Promega, Madison, Wisconsin, 
U SA ) and extracted RNA. After incubation at 37°C  for 
60 min, 80 ^l o f  the PCR mixture was added. The PCR 
mixture contained 50 mmol/l-KCl, 10 mmol/l Tris-HCl 
pH 8.9, 3.6 mmol/l M gCl2, 0.2 mmol/l o f  each 
deoxynucleoside triphosphate, 100 ^g o f  bovine serum 
albumin/ml, 80 pmol o f  sense primer (5'GCA TTT GGA  
CTT GAA CTG TAT G 3'), 40 pmol o f  antisense primer 
and 0.2 units o f  SuperTaq D N A  polymerase (HT 
Biotechnology, Cambridge, UK). Rn A -cD N A  hybrids 
were denatured at 94 °C for 5 min. The amplification was 
performed in 40 cycles consisting o f  denaturation for 1 
min at 94 °C, primer annealing for 1 min at 42 °C and 
elongation for 1 min at 72 °C. The reactions were 
analysed by electrophoresis in 1.5% agarose gels, and the 
300 base pair product was purified from low  melting 
point agarose with the Wizard Clean Up D N A  
purification system  (Promega) according to the 
instructions o f  the manufacturer. D N A  sequence analysis 
was performed using the Ampli Cycle sequencing kit 
according to the manufacturer’s instructions (Perkin- 
Elmer, Foster City, California, USA ). The sequencing 
primer was selected in p2C position 4248-4230 (5'AAC  
CCT ACC GCG CGA GAC GAG 3').
Sequence com parisons. Sequences obtained from the 
virus isolates and published enteroviral sequences were 
analysed for presentation and conservation o f  the 
sequence that encodes for the PEVKEK motif. Analysis 
and alignments o f  the sequences were performed using 
the sequence analysis software package o f  the Genetic 
Computer Group at the University o f  Wisconsin, 
implemented on a UNIX computer. Amino acid 
sequences were deduced from the nucleic acid sequences 
and pairwise compared to the coxsackievirus B4  
sequence described by Jenkins et al. (33).
P ep tide synthesis. Peptides were made on an 
ABIM ED 422 synthesiser (ABIM ED, Langenfeld, 
Germany) using the simultaneous multiple peptide 
synthesis method according to Gausepohl (34). The purity 
o f the peptides was checked on a Rp C18 HPLC 
(LiChrosper, 60RP-select B 5mm, 250 x 4mm, Merck, 
Darmstadt, Germany) and shown to be routinely over
75%.
G eneration o f purified H L A -D R  m olecules. As a
source o f  HLA-DR molecules Epstein Barr Virus- 
transformed B-lymphoblastoid cell lines homozygous for 
HLA-DR were used: LG2.1 (DRB1*0101, DR1), HAR  
(DRB1*0301, DR3), and BSM  (DRB 1*0401, DR4). 
Cells were cultured in RPMI 1640 (GIBCO, Paisley, 
UK), supplemented with 2 mmol/l L-glutamine (GIBCO), 
100 U /100 mg/ml penicillin/streptomycin solution 
(GIBCO), and 10% heat-inactivated fetal calf serum 
(GIBCO). cells were lysed at a concentration o f  108 
cells/ml in 50 mmol/l Tris-HCl, pH 8.5, containing 2% 
Renex (Accurate Chemicals and Scientific Corp.,
Westbury, NY ), 150 mmol/l NaCl, 5 mmol/l EDTA, and 
2 mmol/l phenylmethylsulphanylflupride. The lysates 
were cleared o f  nuclear and other debris by centrifugation 
at 10,000 x g for 20 min. HLA-DR molecules were 
purified by affinity chromatography as described 
previously (35).
H L A-D R -peptide binding assay. The analysis o f  
peptide binding to purified HLA-DR molecules was 
performed using N-terminally fluorescence-labelled  
standard peptides (35). For each o f  the HLA molecules 
different fluorescent-labelled standard peptides were 
used: H A p307-319 (PKYVKQNTLKLAT, DR1), hsp65 
p3-13 (KTIAYDEEARR, DR3) and HA p307-319 Y -F  
(PKFVKQNTLKLAT, DR4). In preliminary experiments, 
each DR preparation was titered in the presence o f  100 
fmol standard peptide to determine the DR-concentration 
necessary to bind 10-20% o f  the total fluorescent signal. 
All subsequent inhibition assays were then performed at 
this concentration. Peptides, o f which the DR  
bindingcapacity was to be determined, were added to 
HLA-DR molecules simultaneously with the standard 
peptide. The HLA-DR-peptide complexes were separated 
from free peptide by gel filtration on a Synchropak GPC 
100 column (250mm x 4.6mm; Synchrom, Inc., Lafayette, 
Ind., USA). Fluorescence em ission was measured at 528 
nm on a Jasco FP-920 fluorescence detector (B&L 
Systems, Zoetermeer, The Netherlands). The percentage 
o f labelled peptide bound was calculated as the amount o f  
fluorescence bound to MHC divided by the total 
fluorescence. Peptides were typically tested at 
concentrations ranging from 66 ^mol/l- 6.6 nmol/l. The 
concentration o f  peptide yielding 50% inhibition o f  
fluorescence (IC50) was deduced from a dose-response 
curve. A  ratio was calculated by dividing the IC5 0  
obtained with the testpeptide by the IC50 o f  the 
corresponding standard peptide. The IC50 o f  the different 
standard peptides were: HA p307-319 (H lA -D R 1): 0.01 
mmol/l; hsp65 p3-13 (HLA-DR3): 0.06 mmol/l; HA  
p307-319 Y -F  (HLA-DR4): 0.2 mmol/l. Binding was 
determined in at least three separate experiments, for each 
peptide-HLA-DR combination.
RESULTS
The PEVKEK sequence is conserved among 
CVB-like enteroviruses. To determine the 
conservation of the CVB sequence that shares 
similarity with GAD65, we determined the amino 
acid sequence 1129-1154 of 10 different CVB4 and 
11 different CVB-like enteroviruses. The sequences 
were compared to the published CVB4 sequence 
(33). The homology of 100 nucleotides in the p2C 
gene was 79% (74% to 85%). The p2C sequences 
of the CVB4 strains had the same degree of 
homology as the sequences of different CVB-like
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Table 1. A m ino acid sequence com parisons o f  
enterovirus isolates.
G A D 65 a m m i a r f k m f p e v k e k g m a a l p r l
Coxsackie B  like enteroviruses
CBV4 FIEWLKVKILPEVKEKHEFLSRLKQL
CBV4 '74 ........................................................N...H.
CBV4 '85 .....................................R ................................
CBV4 '88 ....................R ........N .......
CBV4 '88 ........................................................N .............
CBV4 '89 ........................................................N .............
CBV4 '89 ..............................................................M...
CBV4 '89 ........................................................N .............
CBV4 '90 ..............................................................M...
CBV4 '90 ........................................................N .............
CBV4 '90 ........................................................N.K...
CBV1 ........................................................N .............
CBV1 '81 ........................................................N .............
CBV1 '84 ........................................................N .............
CBV1 '94 ........................................................N .............
CBV2 '93 .........I....................N .......
CBV2 '95 ........................................................NK_____
CBV3 ....................R ........N .......
CBV3 '94 ______F ............R ........N .......
CBV3 '94 ........................................................N ............
CBV5 ..D...........................N .......
CBV5 '92 ..D...........................N .......
CAV9 ....................R ........N .......
CAV9 '94 L ..................R ........N .......
CAV9 '94 ....................R ........N .......
CAV9 '94 LV............................N .......
Echo11 ....................R ........N .......
Echo 9 '97 ..D........V ...............T ........
Polio-like enteroviruses
PV2 ..D. ..E. I.QARD.L.
• X  1 X\. •  • • •
.VTK....
PV1 ..D. ..E. I.QARD.L. .VT..R..
PV3 ..D. .RE. I.QARD.L. .VTK....
CAV2 .VD. ..C. I..A.D.V. ..TK....
Deduced amino acid sequences of protein 2C 28-53 are 
compared to the published CVB4 strain (33). The sequences of 
the various clinical enterovirus isolates are indicated by the 
year of isolation. Non-specified sequences are obtained from the 
EMBL database. Identical amino acid residues are indicated by 
'.'; Non-homologous amino acid residues are indicated by their 
single letter code. The amino acids that are identical with the 
corresponding human GAD65 sequence (amino acid 250-277) 
are depicted in bold.
strains. The d ed uced  am ino acid  sequ en ce in th is 
p2C  region turned out to  be h igh ly  con served  am ong  
the C V B -lik e enteroviruses. The h o m o lo g y  w as  
ob served  varying from  88 to  100%  (m ean 94% ). 
The p o lio -lik e  enteroviruses h ow ever, share less  
h om o lo g y  w ith  the C V B 4  sequ en ce. The am ino acid  
sequ en ce h om o lo g y  in the P E V K E K  region  w as  
59% , and n o  sign ifican t sequ en ce h o m o lo g y  ex ists  
w ith  G A D 65. In T able 1, am ino acid  alignm ents o f  
G A D 65 and the C V B  iso la tes as w e ll as the p o lio ­
lik e  seq u en ces are show n. The P E V K E K  m o tif  w as  
found in all iso lated  viruses. W ith in  the PE V K E K  
m o tif  a sin g le substitution o f  ly sin e  into arginine 
(K  R) w as ob served  in tw o  out o f  10 C V B 4  
iso la tes. T his am ino acid  substitution cou ld  a lso  be 
found in the C V B 3, C V A 9 and ech o  11 iso lates.
The PEVKEK-motif binds to HLA-DR3. T o test  
w hether the h om ologou s seq u en ces b ind to  H L A -  
D R  m o lecu les , p ep tid es w ith  a length  o f  20  am ino  
acids, d educed  from  the G A D 65 protein  and from  the 
corresponding sequ en ces o f  C V B 4 p2C , C V B 3 p2C , 
and from  p oliov irus 3 p2C  (T able 2) w ere generated. 
The pep tid es w ere tested  for b inding to  H L A -D R 1, - 
D R 3, and -D R 4. B ind ing  capacities for the d ifferent 
p eptides are g iven  as ratio o f  the IC50 o f  the test  
peptide com pared to  the IC50 o f  the standard peptide. 
B oth  G A D 65 and C V B  p2C  20  m er p ep tid es bound  
to  H L A -D R  1 -D R 3, and -D R 4 (Table 2). The 
p oliov irus p2C  peptide, w h ich  w as in clu d ed  for  
com parison , bound to  all three H L A -D R  m olecu les. 
Peptide b ind in g  to  H L A -D R  a lle le s  w as confirm ed  
b y evaluation  o f  H L A -D R  b ind in g-m otifs u sing a 
com puter m odel (36) adapted for H L A -D R 3 and 
H L A -D R 4 (37 ,3 8 ). A n  H L A -D R 3 binding m o tif  w as  
found that in clu d es the P E V K E K  sequ en ce and 
som e am ino acids N-term inal o f  both G A D 65 and 
p2C. A n  H L A -D R 4 m otif w as found adjacent to the 
PEV K EK  m otif. The PE V K E K  m o tif as such  
how ever, does not fit w ith the H L A -D R 4 m otif. The 
som e am ino acids N-terminal o f  both G A D 65 and p2C. 
A n H L A -D R 4 m o tif w as found adjacent to  the 
PEV K E K  m otif w as not suspected to bind to  H L A - 
DR1 either (37). To test whether the PEV K E K  m otif, 
rather than adjacent sequences, bind to H L A -D R 1, - 
D R 3 and -DR 4, sm aller peptides o f  12 amino acids 
containing PEV K EK  were generated and tested for 
binding. In contrast to the 20-m er peptides, the smaller 
peptides did not bind to H L A -D R 4 and -DR1.
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Table 2. Binding capacities o f GAD65 peptides and enteroviral p2C peptides to HLA-DR1, DR3 and DR4.
HLA-DR1 HLA-DR3 HLA-DR4
20mer peptides
g a d 65 AMMIARFKMFPEVKEKGMAA 259 267 100
CBV4 p2C FIEWLKVKILPE VKEKHEF1L 187 275 99
CBV3 p2C FIEWLKVKILPEVREKHEFL 136 98 83
PV3 p2C FIDWLRERIIPQARDKLEFV 240 11 55
12-mer peptides
g a d 65 FKMFPEVKEKGM > 300 >
CBV4 p2C VKILPEVKEKHE > 250 >
CBV3 p2C VKILPEVREKHE > 280 >
PV3 p2C ERUPQARDKLE > 80 >
p2C E2-D VKILPDVKEKHE > 10 >
p2C E2-V VKILPVVKEKHE > > >
Binding is expressed as a ratio of the IC50 of the test peptide to the standard peptide. A ratio over 3000 is represented by > and indicates 
no binding. Values shown are the means of at least 3 separate experiments. Standard errors of the mean were < 20%. Peptide sequences 
are depicted by the single letter amino acid code. Amino acids that were suspected to be anchor molecules in HLA-DR3 binding are 
expressed in bold.
However, binding affinity to HLA-DR3 was found 
with comparable affinity as was found with the 20- 
mers (Table 2). In order to investigate whether 
PEVKEK actually bound in the peptide binding groove 
of HLA-DR3, the suspected anchor residue glutamic 
acid on position 2 in the PEVKEK motif (E2) was 
replaced by residues that influence binding affinity. 
Replacement of E2 to aspartic acid (E2 D), which is 
predicted to improve binding with HLA-DR3 indeed 
resulted in an 25-fold increase of binding affinity, 
whereas binding was abolished after replacement to 
valine (E2^ V). These results proof that E2 functions as 
anchor residue in HLA-DR3 binding and confirmed 
the computer predictions. From the HLA-DR3 binding 
motif in PEVKEK it could be ascertained that residue 
K4 also functions as an anchor residue in binding to 
HLA-DR3. In different CVB-like strains the K4 was 
mutated to R (PEVREK). Both, K4 and R4 are 
allowed for binding in the pocket of HLA-DR3 (38). 
Therefore, this mutation was predicted not to change 
binding affinity, which was experimentally confirmed 
(Table 2). The PEVKEK motif contains two of the 
anchor residues needed for binding to HLA-DR3. In
addition the GAD65 and p2C sequences contain a large 
hydrophobic residue N-terminally of PEVKEK that fits 
in the first pocket of HLA-DR3.
DISCUSSION
In this study, it is shown that the viral p2C sequence 
with homology to GAD65, is highly conserved in the 
group of CVB-like enteroviruses. In about 20% of 
these viruses a single amino acid substitution (K->R) 
within the PEVKEK motif could be found. Based on 
computer predictions both K and R are permitted as 
anchor residue in HLA-DR3 binding, which could be 
confirmed by binding experiments (Table 2). Anchor 
residues are usually buried inside the pockets of the 
peptide binding groove and not exposed to the T-cell 
receptor. Therefore this sequence variation may even 
be without consequences for T-cell recognition. The 
binding ratio of the poliovirus p2C peptide appeared to 
be significant. The possibility of cross reactivity, 
however, is not likely since homology with GAD65 is 
very limited. The CVB-like enteroviruses are highly
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prevalent comprising over 90% of the clinical isolates 
that are serotyped in the Netherlands. This implies that 
exposure to the mimicry motif will occur frequently 
throughout life.
In spite of frequent exposure to the mimicry motif, 
antibody responses to GAD65 are rarely found in 
subjects with no risk of developing IDDM (19,20). 
Apparently, other factors such as immune regulatory 
mechanisms and a genetic background may restrict 
cross-reactive responses. With regard to susceptibility 
to diabetes, the genetic association of HLA with 
IDDM might be important. HLA molecules may play a 
role in susceptibility or protection by presentation of 
peptides that either induce or prevent autoimmune 
responses. For the concept of molecular mimicry the 
homologous sequences are required to be presented by 
HLA molecules in a way that cross-reaction can occur. 
As discussed below, the mimicry sequence bound only 
to HLA-DR3 and not to HLA-DR 1 or -DR4, which 
suggests that a putative role of enteroviral infections by 
means of molecular mimicry will indeed be restricted 
by HLA-DR alleles. In support of this finding an 
association has been reported of diabetes with CVB- 
like virus infections in HLA-DR3 positive patients, 
rather than in HLA-DR3 negative patients (39).
Both, the GAD65 peptide containing PEVKEK, as 
well as the viral p2C homologue bound to HLA-DR3. 
It is furthermore shown that the PEVKEK motif as 
such is involved in the specific binding to the peptide- 
binding groove and can be part of a T-cell epitope. 
Moreover, the GAD65 and p2C peptides seemed to be 
located in an identical position within the peptide 
binding groove, a condition required for T-cell cross­
reactivity. Thus, essential conditions for a putative 
cross-reaction between p2C and GAD65 are fulfilled. 
Our data therefore support the hypothesis of molecular 
mimicry as a mechanism involved in autoimmunity to 
GAD65. It remains to be proven, however, whether 
these epitopes can be generated by naturally processing 
and subsequent presentation by HLA-DR3 positive 
cells.
In previous studies, it has been shown that the 
GAD65 sequence with homology to p2C is 
immunogenic and induces T-cell reactivity to GAD65 
in vitro (24,25). Controversy exits as to whether the 
PEVKEK motif itself is recognised, or flanking 
sequences in the peptides. Schloot et al. found a 
positive correlation for reactivity to the GAD65 
peptides designated p17 and p18 that overlapped for
the PEVKEK sequence. This suggests that the 
PEVKEK motif is recognised (25). In the study of 
Atkinson et al, however, reactivity was observed to 
only one of the peptides, suggesting that epitopes 
adjacent to PEVKEK were recognised. In their study, 
T-cell reactivity to p18 was only observed in persons 
positive for HLA-DR4. In support of that observation, 
we found that the small peptide containing PEVKEK 
did not bind to HLA-DR4 whereas the extended 20- 
mer GAD65 peptide did. This suggests that a GAD65 
sequence adjacent to PEVKEK binds to HLA-DR4. 
Taken together, these data imply that HLA-DR4 can 
not be involved in a cross-reactive immune response to 
a sequence with homology to p2C. However, this does 
not rule out that HLA-DR4 positive subjects may elicit 
a response to the homologous sequence through 
presentation by HLA-DQ.
The strongest HLA association with IDDM exists 
for HLA-DQ3.2, for which Kwok et al. recently 
described the peptide binding motif (40). They 
demonstrated that a GAD65-peptide encoded by the 
region with sequence similarity to coxsackievirus p2C 
binds to HLA-DQ3.2. However, large peptides were 
used, and the binding-motif of HLA-DQ3.2 was found 
in a sequence that shares only three amino acids with 
p2C. Binding of the viral p2C peptide was not 
mentioned, but even when the corresponding p2C 
sequence binds to HLA-DQ3.2, the homology will be 
limited and the possibility of T-cell cross-reactivity is 
therefore questionable. However, it should be noted 
that IDDM is a multifatorial disease in which several 
autoantigens and different environmental factors are 
suggested to be involved (2). HLA-DR4 and DQ3.2 
molecules might be involved in other mechanisms in 
the pathogenesis of IDDM.
In animal studies, it has been shown that reactivity 
to GAD65 is a key event in induction and propagation 
of beta-cell autoimmunity in the NOD mouse (41,42). 
In humans however, it is not clear whether 
autoimmunity to GAD65 is associated with induction of 
IDDM. Individuals, who produce solely anti-GAD65 
antibodies, do not seem to progress to IDDM (43,44). 
Furthermore, T-cell reactivity to GAD65 can be found 
in healthy controls as well as recent-onset IDDM 
patients (25). Additional factors seem to be involved 
in the process leading to IDDM.
From studies in transgenic mice it appeared that 
sequence homology alone may not be sufficient to 
break immunological non-responsiveness to
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autoantigens (3,4). According to these studies a natural 
infection can break T-cell non-responsiveness, whereas 
immunisation with the homologous viral antigen did 
not, suggesting that non-specific factors such as local 
inflammation will contribute to the pathological 
process. It was shown that a combination of infectious 
virus, local MHC expression and a tumour necrosis 
factor (TNF)- response in the pancreas were required 
for onset of diabetes in the transgenic mouse (45). 
Recently, other experiments confirmed the important 
role of local inflammation (46). With regard to 
diabetes in humans, it might be important that a virus 
infection can reach the pancreas or even infect - 
cells, in order to give rise to a local inflammation. 
Probably only few enteroviral infections will do so, 
particularly early in life when immune competence has 
still to mature. It has been shown that about 30% of 
CVB-like enteroviruses can damage pancreatic beta 
cells (47). Furthermore, repeated exposure to the 
mimicry motif might be required to break 
immunological tolerance. This is in agreement with the 
observation of a higher rate of enteroviral infections 
during the years before onset of IDDM as compared to 
non-affected controls (12).
Although the evidence remains indirect, our study 
demonstrates that essential requirements for cross­
reactivity between GAD65 and protein 2C of coxsackie 
B-like viruses are met, but only in the HLA-DR3 
positive subpopulation of IDDM patients. It is 
concluded that, besides the epidemiological and 
serological evidence for their role in IDDM, the CVB- 
like enteroviruses also fit conditions for molecular 
mimicry and therefore remain important candidates to 
induce autoreactivity to GAD65.
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protein 2C and the diabetes autoantigen GAD65.
J. Med. Virol. 1999, 59:256-261
Vreugdenhil G.R, Batstra M.R, Aanstoot H.J., 
Melchers W.J.G, and Galama J.MD.

Analysis of antibody responses against coxsackie virus B4 protein 2C and the 
diabetes autoantigen GAD65.
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W il le m  J.G. M e l c h e r s 1, a n d  Jo c h e m  M.D. G a la m a 1.
1 Dept. of Medical Microbiology, University ofNijmegen, Nijmegen, The Netherlands 
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Type I diabetes mellitus results from the autoimmune destruction of insulin producing -cells in 
the pancreas. Certain viral infections, especially those caused by coxsackie B viruses and related 
enteroviruses, have been associated with the development of type I diabetes. The sequence 
homology between the coxsackie B4 virus nonstructural protein 2C (CVB4 p2C) and the major 
diabetes autoantigen glutamic acid decarboxylase (GAD65) provides a basis for the hypothesis of 
molecular mimicry. In this study, we investigated the prevalence of antibodies directed against 
nonstructural enterovirus proteins. In addition, a correlation of antibodies against CVB4 p2C and 
GAD65 was studied in diabetes patients and in healthy controls. Antibody reactivity against CVB 
proteins was detected by immunoprecipitation of [35S]-methionine-labelled viral proteins and 
GAD65 antibodies were measured in a quantitative radio-immuno assay. It was shown that 
antibodies raised against the nonstructural proteins of CVB4 are very common in the population 
and a high degree of heterotypic cross-reactivity exists between different enterovirus types. CVB4 
p2C-specific antibodies were not only detectable in GAD65 antibody positive diabetes patients but 
also in GAD65 antibody negative healthy blood donors. Furthermore, GAD65 antibodies could not 
be detected in p2C-positive subjects who had various enterovirus infections, indicating that an 
antibody response to CVB4 p2C does not necessarily induce a cross-reactive immune response 
against GAD65. A correlation was not found between antibodies against GAD65 and p2C.
Coxsackie B virus infections have been associated 
with the development of type 1 diabetes mellitus. The 
association is based on virus isolations from newly 
diagnosed patients (1,2), induction of hyperglycaemia 
in animals by coxsackie B viruses (CVB) (3-5), and 
sero-epidemiological studies in humans (2,6). Case- 
control studies have shown an increased prevalence 
and elevated levels of IgM antibodies to CVBs in 
newly diagnosed diabetes patients as compared with 
healthy controls, indicating a recent or ongoing 
infection at onset of the disease (6,7). More evidence 
for a role of CVB infections in the disease process was 
obtained from prospective follow-up studies in 
Finland. During the preclinical phase, diabetes patients 
were more frequently infected with CVB than their 
matched controls (8,9). Even intra-uterine exposure to 
the virus has been reported as a risk factor for
development of diabetes mellitus (10). Moreover, 
patients seroconverted for islet cell autoantibodies 
during a CVB infection, suggesting that CVB 
infections triggers autoimmunity (11).
Coxsackie B viruses belong to the family of 
enteroviruses that are common human pathogens that 
usually cause an acute infection. The clinical 
manifestations vary from asymptomatic infections to 
severe medical conditions such as paralysis, 
meningoencephalitis, and myocarditis (12). Whereas 
virus-specific T-lymphocytes are activated during an 
infection (13), antibody responses are pivotal in the 
defence against enteroviruses and are responsible for 
clearance of the infection. Neutralising antibodies are 
directed against the capsid surface of the virus and are 
type specific. It is assumed that antibodies against 
nonstructural proteins of CVB are induced as well, but
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surprisingly little has been published on this subject
(14). Nonstructural proteins are produced exclusively 
during replication of the virus and are released as a 
consequence of cell lysis of the infected cells.
Immune responses against nonstructural proteins of 
enteroviruses may play a role in type I diabetes 
mellitus. It has been suggested that a sequence 
similarity of the CVB4 protein 2C (CVB4 p2C) and a 
major diabetes autoantigen, glutamic acid 
decarboxylase (GAD65), results in immunologic cross­
reactivity, a process referred to as molecular mimicry
(15). GAD65 is a key target antigen in the pathogenic 
process of murine diabetes. In mice, GAD65-specific 
reactivity coincides with the onset of insulitis, and it 
has been shown that diabetes can be prevented by 
tolerisation to GAD65(16,17). One of the immunologic 
determinants of GAD65 is a peptide containing the 
region of similarity with p2C (PEVKEK) (18). T-cells 
responding to this mimicry sequence have been 
demonstrated in non-obese diabetes (NOD) mice and 
in patients with type 1 diabetes mellitus (19-21). 
Autoantibodies against GAD65 are present in the 
majority of newly diagnosed patients, and can be 
detected several years before clinical onset of the 
disease (22,23). It has been shown that antibodies 
induced by CVB4 p2C peptides cross-react with the 
homologous GAD65 peptides (24,25), but the relevance 
for the pathogenesis of type 1 diabetes mellitus is 
disputable (18). The prevalence of naturally induced 
antibodies against p2C has not yet been studied.
In this study, antibody prevalences were analysed 
against enterovirus nonstructural proteins in subjects 
who had various enterovirus infections, in healthy 
individuals, and in newly diagnosed type I diabetes 
mellitus patients. In addition, a correlation between 
antibodies against CVB4 p2C and GAD65 was 
investigated.
S u b j e c t s  a n d  m e t h o d s
Subjects and serum samples. Convalescent serum samples 
were drawn from 26 individuals with a culture proven 
enterovirus infection. The viral infections comprised CVB2 
(2), CVB3 (5), CVB4 (2), coxsackievirus A9 (CVA9) (2), 
ECHO virus 6 (EV6) (1), EV7 (1), EV9 (7), EV11 (2), 
EV25 (2), EV29 (1) and EV30 (1). Paired serum samples 
comprising an acute and a convalescent sample were 
collected from 8 additional patients. The samples were 
collected within a time interval o f 10-20 days. Neutralising
antibody titres were determined routinely and showed a 
significant increase in the convalescent serum samples. The 
patients experienced an infection caused by CVB3 (5), 
CVB4 (1), or EV11 (2) based on virus isolated from the 
throat. The sera were tested for the presence o f antibodies 
against CVB structural and nonstructural proteins and 
GAD65 autoantibodies. Serum samples from 26 healthy 
blood donors were included in the study. Serum samples 
from 22 recently diagnosed type I diabetes mellitus patients 
(mean age 9 years) and samples from 5 nondiabetic siblings 
(mean age 12 years) were obtained. The samples were 
collected within a 3-month time period and were obtained 
from the same geographical region (the provinces Zeeland 
and Holland). All sera were tested for GAD6 5 antibodies and 
antibodies against CVB4 p2C as well as other nonstructural 
enterovirus proteins.
GAD 6 5  antibody assay. Antibodies against GAD6 5 were 
measured by a validated radio-binding assay, performed as 
described previously (26). The results were correlated to 
standard negative and positive control sera and were 
expressed as GAD65 index. Antibody levels were shown as 
the median o f a triplicate. GAD6 5 antibody positivity was 
determined as index > 0.05.
Viruses and labelling of viral proteins. The CVB4 strain 
was a clinical isolate o f which the homology with GAD65 
had been established previously (27). CVB3, CVB4 and 
poliovirus Mahoney strain were cultured and propagated in 
Vero cells. Viral proteins were labelled with [35S]-methionine 
as described previously (28). Extracts o f either CVB3-, 
CVB4-, poliovirus- or mock-infected cells were prepared by 
incubation with a hypotonic buffer for 30 min at 37 °C and 
three cycles o f freezing and thawing. The amount of 
incorporated [35S]-methionine was measured in a liquid 
scintillation counter. Protein labelling was analysed further 
by sodium  dodecyl sulphate-polyacrylam ide gel 
electrophoresis (SDS-PAGE) and autoradiography, as 
described previously (28). Following this procedure, the 
virally infected cell extracts contained labelled proteins that 
were almost exclusively o f viral origin.
Immunoprecipitation of enterovirus proteins. Antibodies 
a g a in s t  v ir a l  p r o te in s  w ere  m ea su red  by  
immunoprecipitation o f  virally infected Vero cell lysates. 
Twenty ^l o f the serum samples were incubated overnight at 
4°C with 200,000 counts per minute o f [35S]-methionine- 
labelled virally infected cell lysates in a total volume o f 100 
^l Tris-buffered saline (pH 7.5) complemented with 0.5% 
Tween-20 (TBS-T). The mixtures were then incubated with 
14.3 mg o f protein A-Sepharose 4B [Pharmacia Biotech, 
uppsala, Sweden] per sample for 2 hours at 4°C. The 
precipitated proteins were washed five times with TBS-T and 
once with ice-cold H20  and analysed by SDS-PAGE and 
autoradiography. The specificity o f the method was 
confirmed by including serum obtained from a pathogen-free 
rabbit. In addition, we tested for nonspecific binding o f the 
viral proteins to the sepharose beads by protein precipitation 
in the absence of serum.
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Rabbit anti-p2C serum. The 2C gene o f CVB4 was 
cloned in the pGEX 4T2 vector and expressed as a 
glutathione S-transferase (GST) fusion protein [Promega, 
Madison, WI]. After purification and cleavage o f the GST 
fusion protein, recombinant p2C was used for rabbit 
immunisation. The rabbits were kept under pathogen-free 
conditions. The rabbit antiserum was tested for specificity by 
immunoblot. The anti-CVB4 p2C serum was used as a 
positive control o f  p2C precipitation.
CVB4 p2C antibody detection. 2C was translated in vitro 
and used for immunoprecipitation. The 2C gene was cloned 
into a pCITE-1 vector behind a T7 RNA polymerase 
promotor [Novagen, Madison, WI]. In vitro translation 
reactions were carried out as described previously (29). Anti- 
p2B rabbit antiserum, kindly provided by K. Bienz, was used 
as a negative control.
R e s u l t s
Antibodies against coxsackie virus B4 proteins.
Serum samples from 26 subjects with a recent, culture- 
proven enterovirus infection, and from healthy donors 
were tested for antibody prevalence against CVB4 
proteins labelled in vivo (Fig. 1A). Antibodies, present 
in the sera obtained from patients with a recent 
enterovirus infection, precipitated the whole range of 
CVB4 proteins: Nonstructural proteins, their precursor
proteins, and capsid proteins were recognised (Fig. 
1B). Antibodies against CVB4 proteins were also 
detected in serum samples from healthy donors, 
indicating that these donors had been exposed to 
enteroviruses previously (Fig. 1C). Some variation in 
antibody reactivity against the nonstructural protein 
p3C was observed. To investigate the presence of 
antibodies against nonstructural CVB proteins, we 
tested paired serum samples, that is, an acute and a 
convalescent sample, exposing a significant raise in 
CVB neutralising IgM antibodies. No difference in the 
overall pattern of precipitated proteins was observed 
between the acute (IgM negative) and the convalescent 
(high IgM titre) serum samples (Fig. 2).
Heterotypic cross-reactivity between different 
enterovirus types. The serum samples tested were 
obtained from patients with various CVA, CVB and 
EV infections. All sera precipitated proteins of the 
CVB4 strain, irrespective of the viral type by which 
the patients were infected. In addition, serum samples 
were tested for precipitation of [35S]- labelled extracts 
from CVB3-, CVB4-, poliovirus-, and mock-infected 
cells. Viral proteins from each of these enteroviruses 
were precipitated, whereas mock-infected lysates were 
not recognised (data not shown). Reactivity against
Figure 1. Immunoprecipitation of CVB4 proteins. (A) in vivo labelling of total CVB4 proteins. (B) CVB4 proteins immunoprecipitated 
by serum from patients with a recent enterovirus infection of different serotypes: lane 1, CVA9; lane 2, EV29; lane 3, EV9; lanes 4 and 
5, CVB4. (C) Lanes 1-5, CVB4 protein precipitation by serum from healthy donors.
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sample n e u t r a l iz in g
nr A b  Ttitre
A1 <4
A2 256
B1 <4
B2 >1024
C1 16
C2 512
D1 8
D2 256
E1 <4
E2 32
F 1 <4
F2 256
Figure 2. Immunoprecipitation of CVB4 proteins by paired serum samples from subjects experiencing a recent enterovirus infection. (A) 
Immunoprecipitation of CVB4 proteins by acute (1) and convalescent (2) serum samples from patients with a recent enterovirus infection 
comprising serotype CVB4 (A), CVB3 (B,C, E and F), and EV20 (D). (B) The titre of neutralising antibodies for each serum sample is 
presented. No difference in overall pattern or intensity of the precipitated proteins between the convalescent and the acute samples was 
observed.
Figure 4. Antibody reactivity against p2C. In vitro translated p2C 
was immunoprecipitated by sera from different subjects. In lane 1 
in vitro translated p2C is shown, indicated by an arrow. 
Immunoprecitation by serum from a pathogen free rabbit (lane 2), 
rabbit anti-p2C antiserum (lane 3), rabbit anti-p2B antiserum 
(lane 4), and precipitation in the absence of serum (lane 5) are 
included as either negative or positive controls. Representative 
results of anti -p2C positivity in GAD65 positive (lane 6), and 
GAD65 negative sera (lane 7) are shown. Sera from enterovirus 
patients (CVB4 lane 8, and EV11 lane 9) and healthy donors 
(lane 10) were positive for antibodies against p2C.
Figure 3. Antibody reactivity against CVB4 proteins in samples 
from type 1 diabetes mellitus patients and their siblings. Antibody 
reactivity against CVB4 proteins was detected in sera obtained 
from type 1 diabetes patients and their siblings as shown by 
representative data from: a GAD65 negative sibling (lane 1); 
GAD65 positive sample from a type 1 diabetes patient (lane 2); and 
a GAD65 negative diabetes serum sample (lane 3). As a control, 
precipitation by a CVB3 infected patient is shown in lane 4.
CVB4 proteins was observed in the GAD65 antibody- 
positive and GAD65 antibody-negative serum samples
(Fig. 3).
Antibody reactivity against p2C. Antibody reactivity 
against p2C was confirmed by precipitation of p2C 
translated in vitro, by which we excluded possible co­
precipitation of the viral p2C with other viral proteins. 
Antibodies against p2C were detectable in all sera 
from diabetes patients and siblings, either GAD65 
antibody positive or negative (Fig. 4). Sera from 
nondiabetic subjects with a recent enterovirus 
infection and sera from healthy subjects did not 
contain antibodies against GAD65 but showed antibody 
reactivity against p2C (Fig. 4).
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The finding that antibodies against nonstructural 
enterovirus proteins are highly prevalent in the 
population, both in patients with a recent infection and 
healthy donors, is not unexpected. The high antibody 
prevalence corresponds with the high frequency of 
enterovirus infections in the population, most 
frequently causing the so-called “summer-flu” or 
inducing subclinical infections (12). Antibodies against 
nonstructural proteins, however, have been 
documented only rarely and possible cross-reactivity 
between nonstructural proteins of different but related 
enteroviruses has not been studied extensively (14). 
We observed that serum samples obtained from 
patients with different enterovirus infections reacted 
with CVB4 antibodies, which suggests a previous 
infection with the CVB4 serotype. However, most 
probably these antibodies are induced by other, related 
serotypes. Based on the relatively conserved sequences 
of nonstructural enterovirus proteins (30,31), a high 
degree of heterotypic cross-reactivity can be expected. 
Indeed, the results strongly suggest the existence of a 
very broad heterotypic cross-reactivity. CVB4 proteins 
were precipitated irrespective of the enterovirus strain 
by which the subjects were infected. Moreover, the 
sera did not differ in their capacity to precipitate other 
enterovirus strains, for example, CVB3 and poliovirus.
The role of antibodies against nonstructural 
proteins in the defence against viral infections is not 
clear. These antibodies might be secondary to virally 
induced cell lysis rather than be involved in the 
clearance of the infection. Because nonstructural 
proteins are exclusively produced during viral 
replication, induction of antibodies against 
nonstructural proteins is dependent on active 
replication of the virus. That makes these antibodies 
attractive components to discriminate between 
immune responses induced by wild-type infection or 
by vaccination with killed virus, for example, against 
poliovirus (14). Such a discrimination would be of 
value in the monitoring of circulating poliovirus in the 
population and the prevalence of subclinical 
poliovirus infections, which are important issues in the 
follow up of the poliovirus eradication programm. 
Whereas none of the subjects had a clinical history of 
infection with poliovirus, and most of the individuals 
were vaccinated with inactivated (nonreplicating) 
poliovirus vaccine, poliovirus nonstructural proteins 
were precipitated by all of the sera (data not shown),
D is c u s s io n indicating that antibodies against enteroviral proteins 
cross-react with the poliovirus nonstructural proteins. 
The high degree of antibody cross-reactivity against 
nonstructural proteins, limits the possibility to use 
antibodies against nonstructural proteins as a marker of 
a natural poliovirus infection.
The sequence homology between p2C and GAD65, 
the major autoantigen in type 1 diabetes mellitus has 
been proposed as a target of immunological cross­
reactive responses. Although it has been shown that 
cross-reactivity against GAD65 and p2C is possible, the 
role in the pathogenesis of type 1 diabetes mellitus is 
not known and there is no consensus whether 
significant differences in p2C antibody reactivity exists 
between diabetes patients and healthy controls (24,25). 
Deletion mutants of GAD65 demonstrated that the 
region of similarity between GAD65 and p2C is 
involved in recognition of GAD65 by GAD65-antibodies 
(18). However, monoclonal antibodies against this 
region, obtained from type 1 diabetes mellitus patients, 
did not cross-react with p2C (18), suggesting that there 
is no involvement of antibody mediated mimicry in 
patients with type 1 diabetes mellitus.
It has been reported that antibodies against GAD65 
are directed mainly against conformational epitopes 
(18). Therefore, studies investigating antibody cross­
reactivity with synthetic peptides, must be considered 
with caution. In our study, we used native p2C, 
translated and processed by virally infected cells, 
which closely resembles the in vivo situation. 
Therefore, it was possible to detect all conformational 
and linear epitopes as expressed naturally in the in vivo 
situation. The p2C antibodies were detected in all of 
the serum samples tested, either GAD65 antibody 
positive or GAD65 antibody negative. The high 
antibody prevalence does not agree with the 
observation by Richter et al. (1994) who detected p2C 
antibodies in only 3 of10 serum samples from patients 
and healthy control donors. The high anti-p2C 
antibody prevalence correlates well with the observed 
reactivity against other nonstructural proteins of 
enteroviruses.
GAD65 antibodies were not detectable in healthy 
controls or subjects with a recent enterovirus infection, 
although p2C antibody positive, indicating that 
reactivity against CVB4 p2C does not necessarily 
induce a cross-reactive immune response with GAD65. 
As a consequence of the high prevalence of anti-p2C 
reactivity, a correlation between p2C antibodies and 
GAD65 antibodies cannot be established.
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Several remarks have to be made concerning the 
lack of association between GAD65 and p2C antibody 
reactivity and the relevance of molecular mimicry for 
the development of type I diabetes mellitus. First, 
based on a genetic predisposition, subjects at risk of 
development of type 1 diabetes mellitus may direct 
their immune response to different CVB4 p2C epitopes 
(e.g. the PEVKEK region) as compared with subjects 
not as risk for the disease. It has to be determined 
whether in type 1 diabetes mellitus patients anti-p2C 
antibodies are directed against the homologous region. 
As yet, antibodies against the homologous region of 
GAD65 obtained from type 1 diabetes mellitus patients 
have not been shown to cross-react with p2C (18). 
Second, animal experiments have shown that a high 
variety in diabetogenicity of different CVB strains 
exists probably due to differences in tissue tropism of 
the virus (3,32,33). By testing antibodies against viral 
proteins we cannot distinguish between diabetogenic 
and nondiabetogenic variants. A combination of 
several viral factors, for example, the frequency and 
localisation of coxsackie B viral infections, and the 
antigenic determinants of the virus are factors that may 
all contribute to the development of type I diabetes 
mellitus (34,35). Third, antibody responses against 
GAD65 may be secondary to beta-cell destruction 
rather than being initiators of autoimmune destruction 
of the insulin producing cells (36). The cellular 
immune response might be more relevant in the 
pathogenesis of type 1 diabetes mellitus than 
antibody-mediated molecular mimicry (37).
In conclusion, the results demonstrate that antibody 
reactivity against p2C is highly prevalent in the 
population and does not generally cross-react with
GAD65.
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Enterovirus infections have been implicated in the development of type 1 diabetes mellitus. They 
may cause ß-cell destruction either by a cytolytic infection in the pancreas or indirectly by 
contributing to autoimmune reactivity. We have sought evidence for these two mechanisms in a 
case of acute onset of diabetes during a severe ECHO virus type 9 infection. The virus was isolated 
and administered to cultured human -cells. No viral proliferation was observed, and no -cell 
death was induced, while parallel exposure to coxsackievirus B3 resulted in viral proliferation and 
massive ß-cell death. Although the viral protein 2C exhibited a sequence similarity to that of the 
ß-cell autoantigen glutamic acid decarboxylase (GAD65), no cross-reactive T-cell responses were 
detected. The patient did not develop antibodies to GAD65 either. Absence of evidence for a direct 
cytolytic action or an indirect effect through molecular mimicry in the present case raises the 
possibility of another indirect pathway through which enteroviruses can cause diabetes mellitus.
The incidence of type 1 (insulin dependent) diabetes 
(type 1 DM) is increasing rapidly in many parts of the 
western world (1). Studies in monozygotic twins clearly 
indicated that environmental factors play a role in 
addition to the genetic susceptibility for the disease (2). 
The pathogenesis of the disease involves autoimmune 
mechanisms with environmental risk factors contribute 
either in initiating autoimmunity or accelerating an 
already ongoing ß-cell destruction (3,4). One of the 
major environmental risk factors disclosed by 
epidemiological studies is infection by enteroviruses, 
mainly coxsackie B viruses (CVB) (5,-7). Case studies 
showed that enteroviruses indeed can cause acute onset 
of diabetes (7,8). In addition, recent prospective studies 
suggest that children who develop type 1 diabetes 
mellitus acquire more frequent enteroviral infections, 
than do their healthy siblings (9,10). Moreover, these 
studies showed that seroconversion to, or elevation of 
autoantibodies against islet cell antigens was 
temporarilly related to enterovirus infection, suggesting 
that viral infection triggers autoimmunity to the 
pancreatic -cells (3).
The way that enteroviruses may trigger 
autoimmunity and the onset of type 1 diabetes mellitus 
is not clear. Several mechanisms that are not mutually 
exclusive have been suggested. First, enterovirus 
infection in the pancreas may cause direct ß-cell lysis 
by the cytotoxic lifecycle of the virus (11,12). Second, 
T-cells may cross-react, which occurs when viral and 
self-antigens share antigenic determinants, a process 
termed molecular mimicry (13-17). On the basis of 
sequence similarity in the CVB protein 2C and the - 
cell antigen glutamic acid decarboxylase (GAD65), 
putative cross-reactivity has been suggested to be 
involved in the development of type 1 diabetes mellitus 
(13,14). Furthermore, as demonstrated in animal 
models, viral infections can activate potentially self­
reactive T-cells (18), a process described as bystander 
activation. Alternatively, viral infections may locally 
induce production of cytokines and other inflammatory 
mediators which may affect -cells directly by their 
toxic effects (19,20). The first pathway does not 
necessarily imply autoimmune responses; however, 
subsequent to -cell damage and antigen uptake by
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antigen presenting cells, reactivity against ß-cell 
components may well occur.
We investigated the role of enteroviruses in the 
development of type 1 diabetes mellitus in a six weeks 
old girl with acute-onset of type 1 DM, during 
generalised, severe infection with echovirus type 9 
(EV9). The virus was isolated and tested for its 
cytotoxic effect on human -cells isolated from donor 
organs. The child’s genetic susceptibility for the disease 
was assessed by HLA typing. Sequencing of the 
encoding region of the viral protein 2C (p2C) disclosed 
sequence homology with GAD65. Crossreactivity 
between p2C and GAD65 was therefore investigated by 
a T-cell proliferation assay. After recovery from the 
infection and stabilisation of the diabetic state, the child 
underwent testing of the presence of autoantibodies to 
islet cell antigens as well as autoreactive T-cells.
PATIENT AND METHODS
Case history. A  6-week-old girl presented to our hospital 
with signs o f dehydration and lethargy. Before admission, she 
had fever (temperature up to 39.50 C) with diarrhea for 3 days 
and did not drink well. The pregnancy and delivery were 
uneventful (birth weight, 2934 g). The child was breast- fed. 
The girl was admitted to a children’s ward for treatment of  
suspected gastro-enteritis with imminent dehydration. A  blood 
sample for chemistry analysis was obtained before 
intravenous rehydration therapy was started, and throat and 
nose swabs were obtained for hematologic analysis, serology, 
and microbiological cultures. At the time o f admission, an 
electrencephalogram was normal, but on the next day she 
developed symmetrical seizures o f short duration for which 
she was treated with phenobarbital for 10 days. Because of 
suspected meningitis, a CSF specimen was obtained by 
lumbar puncture and treatment with antibiotics was started.
Laboratory values. Blood chemistry revealed elevated levels 
of C-reactive protein (25 mg/l) and glucose (27.4 mmol/L). 
Levels o f hemoglobin A1c (5.3%) and C peptide Z(0.06 
nmol/L) were not elevated. The analysis disclosed the 
following values: H C 03, 23 mmol/L; base excess, -2 
mmol/L; pH, 7.31; alanine amino-transferase, 71 U/L; 
aspartate aminotransferas, 87 U/L; alkaline phosphatase, 416 
U/L; lactate dehydrogenase, 334 U/L; amylase, 9 U/L; and 
triglyceride, 42.6 mmol/L. The leukocyte count was 14.2 x 
109/L, (10.8x109/L lymphocytes; 0.8x109/L monocytes). The 
platelet count was 478x109/L, and the hemoglobin level was 
5.8 mmol/L. Analysis o f CSF showed the following: 
leukocyte count, 31/^L; glucose level, 15.6 mmol/L; and 
protein level, 0.84 mg/L. Bacterial cultures o f nose swabs 
revealed Haemophilis influenzae. Cultures o f throat swabs 
demonstrated normal flora. Viral cultures from throat, feces, 
and CSF yielded EV9.
Hyperglycemia appeared to be due to insulin dependent 
DM. Insulin treatment was started (dose, 1.26 U/kg/day). The 
need for insulin remained during the patient’ s first year of 
life (dose, >1 U/kg/day). The triglyceride values normalised. 
Furthermore, a low amylase level (9 U/L) excluded 
pancreatitis, but the liver enzyme levels suggested mild 
hepatitis. There was no family history o f type 1 DM. It was 
concluded that the girl had gastro-enteritis, dehydration, and 
meningo-encephalitis due to generalised e V 9 infection. 
During the EV9 infection, she developed acute-onset 
diabetes mellitus without clinical remission. At the age o f  8 
months, the child appeared to be retarded with signs o f a 
mild quadriplegia, which was attributed to meningo­
encephalitis. Furthermore, she developed epilepsy and 
severe psychomotor retardation.
Viruses and cells. EV9 was isolated from throat, fecal and 
CSF specimens from the patient. The isolate was serotyped 
with use o f serum pools obtained from the National Institute 
for Public Health and Environment (RIVM) as described 
elsewhere (21). The virus was propagated on tertiary monkey 
kidney cells (TAN). A  clinical CVB serotype 4 isolate and 
virus derived from infectious cDNA clone from CVB 
serotype 3 (Nancy strain) pcB3/T7 (22) were propagated on 
Vero cells; these isolates were used for comparison. The cells 
were grown in minimal essential medium (MEM) 
supplemented with 10% fetal bovine serum.
Isolation o f viral RNA and sequence analysis. Viral RNA  
was extracted after a single passage o f the virus with 
guanidinium thiocyanate-phenol-chloroform according to the 
method o f Chomczynski & Sacchi (23). Reverse 
transcriptase and PCR analysis o f the 5 ’ NTR and 2C 
genome were performed as described previously (15,24). The 
2C sequence coding for the region with homology to GAD65 
were analysed by sequence analysis as described elsewhere
(15).
Preparation and culture of human ß-cells. Pancreatic islets 
were isolated from 4 human donors (8, 16, 53 and 81 years 
old) as described previously (25). Islet suspensions were 
obtained by dissociation o f freshly isolated cells in calcium­
free medium with trypsine and DNAse. Preparations of 
single -cells and non-endocrine islet cells were collected 
after autofluorescence-activated cell sorting (25). This 
procedure resulted in cultures containing 63 ± 4% ß-cells. 
The purified cells were cultured under serum-free conditions. 
The medium consisted o f Ham’s F10 medium [Gibco 
laboratories, Grand Island, New york] supplemented with 2 
mM L-glutamine, 50 mM 3-isobutyl-1-methylxanthine, 0.075 
g/L penicillin, 0.1 g/L streptomycin, 7.5 mM glucose, and 10 
g/L charcoal-treated BSA.
p-cell viability assay. The percentage o f viable, necrotic, or 
apoptotic cells was assessed following culture in the presence 
of virus. Exposure time varied from 2 hours to 7 days. The 
cytotoxicity test is based on fluorescent staining o f nuclei 
with Hoechst 33342 [Calbiochem-Novabiochem, La Jolla, 
CA], and propidium iodide [Sigma, St. Louis] (26). 
Apoptotic cells were detected by their fragmented nuclei.
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Beta cells were infected with EV9 at a multiplicity of 
infection (MOI) o f 10 TCID50 per cell or CVB3 at an m Oi o f 
10, 1, or 0.1 TCID50 per cell or were not-infected.
Virus replication in islet cells. Single-cycle growth curves 
were determined by infecting 20,000 pancreatic islet cells 
with the virus at an MOI o f 1 TCID50 per cell, and viruses 
were yielded at different time points after infection. Virus 
yields were titrated on TAN cells in 96-well plates as 
described elsewhere (27). TCID50 values were calculated 
according to the method o f Reed and Munch (27).
Determination of HLA. HLA-DQA1 was determined by 
PCR based techniques using the Ampli Type HLA-DQalpha 
Forensis DNA Analysis kit [Perkin-Elmer, Ranchburg, NJ] 
according to the manufacturer’s instructions. HLA-DQB1 
was determined as described previously (28). HLA-DR was 
assigned by linkage disequilibrium.
Autoantibodies. Serum samples were obtained from the 
patient 2 and 8 months after the onset o f type 1 DM. Levels 
o f autoantibodies to the protein tyrosine phosphatase (IA-2), 
and islet cell antigen (ICA) were measured by validated 
methods as described elsewhere (29). The presence of 
antibodies to a glycosylated islet cell membrane antigen 
(GLIMA3 8 ), which together with GAD6 5 and IA-2 marks the 
early phase o f autoreactivity in type 1 dM , was determined as 
described elsewhere (30). Levels o f antibodies to GAD65 were 
determined by using a validated radio binding assay as 
described elsewhere (31). All sera were tested in triplicate.
Lymphocyte proliferation assay. Fresh peripheral blood 
mononuclear cells (PBMC) were isolated by Ficoll 
centrifugation [Ficoll-paque, research grade; Amersham 
Pharmacia Biotech AB, Rozendaal, The Netherlands] 2 and 8 
months after the onset o f type 1 DM. T-cell responses were
measured by a lymphocyte proliferation assay as described 
bySchloot et al. (32). In brief, PBMC were cultured for 6 
daysin Iscove’s modified Dulbecco’s medium [Gibco BRL, 
Paisely, Scotland] containing 10% autologous serum. 
Antigenreactivity o f the PBMC was tested in triplicat in 
presenceof medium (background proliferation), IL-2 (10%) 
(positive control), recombinant human islet antigens IA-2 10 
^g/mL and GAD65 10 ^g/mL, GAD65 peptides (3 ^g/mL), 
IA-2 peptides (3 ^g/mL), cell lysate retrieved from CVB4 
infected Vero cells, mock-infected cell preparation, or CVB 
p2C peptides (3 ^g/mL). After 5 days o f incubation, [3H]- 
thymidine was added to the cells and the incubation was 
continued for 18 h. Cultures were harvested and [3H]- 
thymidine incorporation was measured by liquid scintillation 
counting. The results are shown as the median o f the finding 
of the 3 tests. Reactivity was considered significant if  the 
stimulation index (SI, cpm with antigen/cpm without antigen) 
was >3.
Antigens. Human recombinant GAD65 and the immunogenic 
region o f IA-2 (representing amino acid 605-979) were 
prepared as described (33,34). A  panel o f peptides (Table 1) 
spanning the homologous amino acid sequence o f human 
GAD65 and CVB p2C was synthesised by solid phase 
strategies on an automated multiple peptide synthesiser 
[Abimed Analyses- Technik, Langenfeld, Germany] (35).
Cell lysates were prepared by infecting Vero cells with a 
high dose o f CVB4 (MOI, 50 TCID50 per cell). After 
complete cytopathic effect was reached, the infected cells 
were collected by trypsine treatment. In the meantime mock- 
infected cells were prepared. The cells were washed twice 
with PBS anddissolved in PBS (concentration, 104 cells/mL). 
Virus was released by three cycles o f freezing and 
thawing.This procedure resulted in a viral yield o f 109 
TCID5 0 /ml.
Table 1. Overlapping peptides covering the sequence common to glutamic acid decarboxylase (GAD65) 
and coxsackie B virus serotype 4 protein 2C (CVB4-p2C).
Peptide, amino acid position Amino acid sequence
g a d 65
247-266 p17 NMYAMMIARFKMFPEVKEKG
251-270 MMIARFKMFPEVKEKGMAAL
253-273 IARFKMFPEVKEKGMAALPRL
260-279 p18 PEVKEKGMAALPRLIAFTSE
261-280 EVKEKGMAALPRLIAFTSEH
CVB4 peptide
30-49 CVB4-p2C WLKVKILPEVKEKHEFLSRL
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Figure 1. Necrosis induced by enterovirus infections in cultured 
human islet cells after 24 hours (open bars), 48 to72 hours (black 
bars) and 6 to 7 days (grey bars). The mean necrosis index of 4 
separate experiments is shown. The index corrects for the amount of 
necrotic cells in the mock-infected controls. The mean percent of - 
cells within the islets was 63 ± 4%. Statistical significance of 
differences was calculated by paired t-test: * p<0.05, f  p<0.01, J 
p<0.001.
RESULTS
Viral infections of cultured human pancreatic islet 
cells. To investigate whether the isolated virus exhibits 
tropism for the pancreas and is able to cause direct 
destruction of pancreatic ß-cells, we infected cultures 
of pancreatic islet cells isolated from several human 
donors in an in vitro system. The percentage of ß-cells 
that remained viable or became necrotic or apoptotic 
after virus infection was determined at several time 
points after infection. The patients isolate did not 
induce necrosis and ß-cell death, whereas CVB3 (a 
control enterovirus) did (Fig. 1). No signs of apoptosis 
were observed after infection with either EV9 or CVB 
(apoptosis index <7%). To further investigate whether 
the virus could infect and replicate in -cells without 
cytopathic effects to the host cell, growth of EV9 was 
analyseded in separate experiments that used pancreatic 
islet cells from different donors. No virus growth was 
observed in islet cells from different donors. No virus 
growth was observed in the islet cell fraction enriched 
for endocrine cells or in the non-endocrine fraction. 
Representative results are shown in Fig. 2. In contrast, 
the amount of CVB3 increased significantly (Fig. 2).
hours post infection
Figure 2. Enterovirus replication in cultured human islet cells. A 
representative growth curve of EV9 virus (circles) and CVB3 
(squares) in human islet cell cultures is shown. Viral load was 
determined at the indicated time points post infection. Note that 
the scale is represented as log scale.
The results indicate that the virus isolated from the 
patient was not able to infect and kill the pancreatic ß- 
cells.
Autoantibody reactivities. To test whether 
autoimmunity was triggered by viral infection, we 
investigated the presence of autoantibodies 2 and 8 
months after the onset of type 1 DM. Serum was tested 
for antibodies to IA-2, GAD65 and GLIMA38 (which are 
early markers of autoimmunity) and also for antibodies 
to islet cell antigen. At both timepoints, however, no 
reactivity to these autoantigens was found.
Molecular mimicry. To test the hypothesis of 
molecular mimicry, the viral p2C sequence was 
analysed for homology with GAD65. The virus encoded
GAD«
CVB4-p2C
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Figure 3. Sequence alignment of the mimicry sequence in ECHO 
virus 9 (EV9), Coxsackievirus B4 (CVB4) and glutamic acid 
decarboxylase (GAD65). Solid lines enclose identical amino acid 
residues. Dashed line enclose amino acids with similar polarity, 
hydrophobicity or charge. Numbers refer to the number of amino 
acid residues from the amino terminus of each protein.
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Figure 4. T-cell proliferation of freshly isolated peripheral blood mononuclear cells (PBMC) upon in vitro stimulation with human GAD65 
(hGAD65), Coxsackie B virus, and human tyrosine phosphatase (hIA-2). The tested peptides are indicated by their amino acid number 
from the amino terminus of the protein. T-cell proliferation was tested 2 (open bars), and 8 months (black bars) after onset of type 1 
diabetes. Statistically significant (SI > 3) responses are indicated by *.
the PEVKEK motif, which is shared between GAD65 
and p2C of the CVB-like enteroviruses with some 
minor differences in the flanking sequences (Fig. 3).
The presence of sequence homology in an EV9 
isolate confirmed earlier observations showing that 
EV’s and CVB’s are closely related at a molecular 
level and that many CVB-related viruses contain the 
PEVKEK sequence (15). It was suspected that the 
differences in the flanking sequences did not affect 
binding of the sequence to HLA-DQ8, on the basis of 
the DQ8 binding motif described by Oiso et al. (36).
Genetic backgound. HLA-typing for susceptibility 
markers for type 1 diabetes mellitus was performed. 
HLA-alleles have been shown to bind a putative cross­
reactive epitope that CVB-like viruses have in common 
with GAD65. The typing revealed the high risk 
haplotype HLA-DQ8 (A1*02/B1*0302)-HLA DR4 
haplotype and the protective haplotype HLA-DQ6 
(A1*03/B1*0602)-HLA-DR2(15).
Cellular reactivity. T-cell reactivity was measured 2 
and 8 months after the onset of the disease. Molecular 
mimicry was investigated by measuring T-cell 
responses to GAD65, GAD65 peptides, and viral 
antigens. The proliferation measured in response to 
GAD65, or the GAD65 derived peptides representing 
amino acids 247-266, 251-270, 260-279 and 253-273 
(Table 1) was not different from background 
proliferation. Weak reactivity (SI, 3.7) was measured 
for the GAD65 peptide representing amino acids 261­
280 at 2 months but not at 8 months. Reactivity to CVB 
p2C representing the amino acids 30-49 was also 
slightly increased (SI, 3.1) at 2 months but not at 8 
months (Fig. 4). Reactivity to CVB4 p2C representing 
the amino acids 31-50 was tested at 2 months only, and 
there was no increased proliferation. PBMC 
proliferated in the presence of enterovirus infected cells 
but not in response to the mock-infected preparation. 
Furthermore, T-lymphocytes proliferated in the 
presence of IL-2, islet autoantigen IA-2 at both 2 
months (SI, 7.7) and 8 months (SI, 4.5), and the
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immunogenic region of IA-2 (representing amino acids 
831-860) at 2 months (SI, 9.3) (Fig. 4). The results 
show that reactivity to islet autoantigens could be 
observed in this patient, but T-cell cross-reactivity to 
GAD65 and CVB p2C was not detected.
DISCUSSION
The coincident onset of type 1 diabetes mellitus during 
a severe infection with EV9 strongly suggests a causal 
relationship between the viral infection and type 1 
diabetes mellitus in this patient. The absence of 
characteristic autoantibodies and a normal level of 
glycated haemoglobin (HBA1c) suggest that the child 
was not in a pre-diabetic state with ongoing -cell 
damage and impaired insulin production. There was no 
history of particular medication during the fetal or 
postnatal period. Although enterovirus infections are 
quite common during the first years of life, the severe 
course of infection with retardation due to 
meningoencephalitis is relatively uncommon.
In 1979, it was reported for the first time that 
enteroviruses can cause type 1 DM (8). CVB4 was 
isolated from the pancreas of a child who died from 
diabetic ketoacidosis. In addition, it was shown that the 
virus induced insulin dependency in mice, thereby 
fulfilling Koch’s postulate (7). It was suggested that the 
virus invaded the pancreas and destroyed pancreatic ß- 
cells by viral cytolyses. Repeatedly, CVB antigens have 
been found in -cells after fatal infections (37,38), 
indicating that these viruses infect ß-cells in vivo. Other 
studies failed to demonstrate enterovirus antigens in the 
pancreas (39,40). In vitro studies reported that about 
30% of the CVB4 strains have a tropism for the murine 
pancreas (11) while other serotypes (CVA7, CVA9, 
CVB5) have been shown to destroy mouse -cells as 
well (12). In the present case, the isolated EV9 was not 
found to kill pancreatic -cells from normal human 
donors in vitro, whereas CVB3, that was used as a 
control induced massive necrosis. Although we could 
not test for infection of the patient’s pancreatic cells, 
the virus does not seem to exhibit tropism for human 
donor pancreatic islet cells. The inability of EV9 to 
infect human -cells raises the question whether -cell 
destruction was induced by an indirect pathway.
Enteroviruses may play a role in initiation of -cell 
destruction by inducing a cross-reactive response 
against the ß-cell autoantigen GAD65, a process referred
to as molecular mimicry. The homologous sequence in 
the 2C protein of CVB and GAD65 is a T-cell epitope in 
the non-obese diabetic (NOD) mouse and its 
presentation is related to the murine MHC class II allele 
1-Anod, which confers susceptibility for diabetes 
mellitus (41). Other studies have suggested that this 
epitope is recognised by T-cells in patients with type 1 
diabetes mellitus as well (14,32), although T-cell 
reactivity to this epitope was also found in healthy 
subjects (32). The isolated EV9 encoded the p2C with 
a sequence similar to that of GAD65, making this case 
interesting for investigating the hypothesis of molecular 
mimicry. In addition, there was genetic encoding for 
the high risk HLA-DQ8 allele in this case, which can 
bind the mimicry peptides derived from either the virus 
protein 2C and GAD65 (36). Thus, critical prerequisites 
for molecular mimicry were met in the case. However, 
we did not detect cross-reactive immune responses to 
GAD65 and CVB p2C in the child, despite a strong T- 
cell reactivity against virus-infected cells. T-cells 
reactive to GAD65 or peptides from the homologous 
region of either GAD65 and p2C were not detected 
shortly after clinical onset (2 months), or 8 month later. 
This finding suggests that molecular mimicry with 
GAD65 and CVB p2C did not contribute to -cell 
damage and subsequent insulin dependency.
It must be noted that by testing peripheral blood 
lymphocytes we could have missed the -cell-reactive 
T-cell fraction that moved from the periphery to home 
in the pancreas. Furthermore, at the tested time points, 
the antigen-specific T memory cells might have been 
lower than the detection level. It can be speculated that 
the protective HLA-DR2(15) allele, which has been 
shown to bind GAD derived epitope 248-257 as well 
(42), competed for binding of the mimicry peptides to 
DQ8 and provided a dominant protective effect over T- 
cell reactivity.
Virus-induced type 1 diabetes mellitus can also be 
explained by the bystander hypothesis. Viral infections 
may have the potential to induce proinflammatory 
responses with activation of lymphocytes and 
professional antigen presenting cells, which are crucial 
for an effective immune response (43). This potential 
may result in bystander activation of potentially 
autoreactive T-cells and loss of tolerance to -cells 
(18). This bystander activation may take place either 
locally in the target organ or in the draining lymph 
nodes (44). Furthermore, locally produced cytokines 
and other inflammatory mediators are selectively toxic
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for the -cells, causing additional bystander killing 
(45,46). In the present case, the absence of pancreatitis 
or islet cytotoxicity would rather argue for a peripheral 
or systemic effect on potentially autoreactive T-cells. 
This mechanism might explain the presence of IA-2 
specific autoreactive T-cells in the child, although IA-2 
reactivity can also be found in healthy subjects (33).
It can also be speculated that a generalised viral 
infection systemically modulates the immune response 
towards a Th1 cell-like response with activation of the 
cellular arm of the immune system over humoral 
immune responses (47). A powerful shift of the 
immune response towards cellular activation may cause 
a loss of regulatory cells and a rapid development of 
diabetes mellitus (48). The absence of autoantibodies 
against islet antigens despite apparent -cell 
destruction, as indicated by loss of insulin producing 
capacity, is consistent with a bias toward detriment of 
Th2 cells.
In conclusion, this study reports development of type 1 
diabetes mellitus during a severe systemic infection 
with the EV9 enterovirus At variance with previously 
reported cases of enterovirus-induced diabetes, no 
evidence was found in favour of a direct cytolytic 
effect of the virus on human ß-cells; the patient did not 
have signs pointing to an autoimmune reaction initiated 
by molecular mimicry with the ß-cell antigen GAD65. 
Further studies should examine the possibility that 
enteroviruses like EV9 can cause ß-cell destruction 
through indirect pathways.
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Enteroviruses are associated with chronic inflammatory and autoimmune diseases in humans. In 
these conditions, the cytokine network is supposed to have an important role in inflammation and 
modulation of the (auto)immune response. In the present study, we demonstrate that coxsackie 
virus B4 and poliovirus type 1 induce production of pro-inflammatory cytokines IL-1ß and TNF-a 
in freshly isolated human leucocytes. Furthermore, enteroviruses stimulate the production of 
cytokines belonging to Th1 pathways (IFN-y, IL-2), and IL-10, which play a role in regulation of 
the cellular and humoral immune response.
Enteroviruses are common human pathogens that 
usually cause sub-clinical or mild infections. However, 
enteroviral infections have been implicated in chronic 
inflammatory diseases like polymyositis, chronic 
myocarditis and type 1 diabetes mellitus as well (1).
Cytokines are important mediators aimed to trigger 
immune mechanisms responsible for counteracting the 
growth of micro-organisms inside the host. The balance 
of cytokines of the T helper 1 and T helper 2 subset is 
important in the regulation of cellular and humoral 
components of the immune system. Pro-inflammatory 
cytokines play a role in inflammation and induction of 
the immune reponse. However, when pro-inflammatory 
cytokines are synthesised in overwhelming quantities 
or chronically, it may have deleterious effects in acute 
(septic shock) (2), or autoimmune diseases (reumatoid 
arthritis, type 1 diabetes, inflammatory bowel disease) 
(3-5). In this paper, we studied cytokine responses 
induced by enteroviruses in PBMC from healthy 
donors.
M a t e r ia l s  a n d  M e t h o d s
Isolation of PBM C and culture conditions. Venous blood 
was drawn from healthy donors. Peripheral blood 
mononuclear cells (PBMC) were isolated from EDTA-treated 
blood by Ficoll-hypaque (Pharmacia Biotech AB, Uppsala,
Sweden) gradient centrifugation. PBMC were washed twice 
in PBS and resuspended in culture medium (RPMI 1640 
Dutch modification, ICN, Biomedicals, Inc., Ohio, USA) 
supplemented with 100 ^g/ml gentamicine, 2 mM L- 
glutamine, and 1 mM pyruvate. For short-term incubation 
(<48 h), the cells were cultured under serum-free conditions. 
Culture medium for cells, incubated for 6 days was 
supplemented with 10% heat-inactivated autologous serum. 
Cells were incubated in duplicate at 2.5x105 cells/well in 96 
wells polystyrene plates (Greiner B.V., Alphen a/d Rijn, The 
Netherlands) at 37oC and 5% CO2 in a total volume o f 200 
^l/well. The supernatants were collected after incubation at 
the indicated time points, and stored at 80oC until cytokine 
measurement.
Antigenic stimuli. A  clinical CVB4 isolate and poliovirus 
type 1 (Mahoney strain) were used to test cytokine responses 
against enteroviruses. The virus preapartions were purified 
by high speed centrifugation on a 30% sucrose cushion. A  
control preparation, purified from mock infected cells did not 
result in cytokine release. A  potential endotoxin 
contamination was controlled by preincubation with 
polymyxin B (data not shown). For inactivation by UV  
irradiation, virus preparations were exposed to U V  light at a 
distance o f 20 cm (UV dose =250 mj) in a GS Genelinker 
(BioRad, Laboratories). The loss o f infectivity was 
ascertained by the lack o f viral replication. Responses to 
tetanus toxoid (TT; 1 ^g/ml) (SVM, Bilthoven, The 
Netherlands) were studied as control antigen for T-cell 
responses. Pokeweed mitogen (PMA; (50 ng/ml) + 
ionomycin (1 ^g/ml)) was used as a control for T-cell 
proliferative capacity, and lipopolysaccharide o f E.coli 
serotype 055B5 (Sigma Chemical Co, St Louis, MO) (LPS;
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Figure 1. Production of pro-inflammatory cytokines by CVB4- 
exposed PBMC. Human PBMC were exposed to purified CVB4 
at indicated MOI. After 24 h. of incubation, culture supernatants 
were harvested, and the content of IL-1ß (A), and TNF-a (B) was 
determined. Values are representative of 4 different PBMC donors 
and are the mean ± SD of 4 identically prepared cultures. The 
spontaneous release of cytokines in medium alone, and the 
production of LPS- induced cytokines are presented as indicated.
1 ng/ml) was used as control antigen for cytokine production 
by PBMC.
Cytokine measurements. A  double-antibody sandwich 
enzyme-linked immunosorbent assay was used to measure 
human IL-1ß, TNF-a, IFN-y, IL-2, IL-4, and IL-10 according 
to the instructions o f the manufacturer (Pelikine Compact™ 
human cytokine ELSISA kit, CLB, Amsterdam, The 
Netherlands). Extinction was measured in an ELISA reader 
(Merlin Titertek Multiskan, Rotterdam, the Netherlands) at 
450 nm. To minimise analytical errors, all samples were 
analysed in the same run in duplicate. In order to correct for 
spontaneous cytokine release, the net production was 
calculated by subtracting the concentration without stimulus 
from those induced by various stimuli.
R e s u l t s  a n d  d is c u s s io n
In the present study, we demonstrated that 
enteroviruses activate PBMC to produce the pro- 
inflammatory cytokines IL-1ß and TNF-x, which are
T N F - a  (p g /m l)
120*
100* T
■llll
4 8  18 24 48
hours post exposure
Figure 2. Time course of cytokine production and release from 
CVB4-exposed PBMC. Human PBMC were exposed to CVB4 at 
MOI 10, and release of IL-1ß (A) and TNF-a (B) was determined 
at the indicated time intervals. Spontaneous cytokine release is 
subtracted from the CVB-induced cytokine production. Values are 
the mean ± SD from duplicates of 4 different donors.
involved in inflammatory processes. Exposure of 
PBMC to different concentrations of virus resulted in a 
dose-dependent release of cytokines (Fig. 1). A kinetic 
analysis of CVB4-induced cytokines showed that IL-1ß 
release was detected at 18 h. post infection whereas 
TNF -a could be detected as soon as 4 h. after exposure.
Both cytokines reached their optimum at 24 h. post 
infection. The virus did not replicate in PBMC, and 
immune fluorescence staining with an enterovirus- 
specific antibody was negative (data not shown), which 
does not confirm the observation of Henke et al.(6), 
who described that a subset of monocytes can be 
infected and produce small amounts of virus. Our 
results are in line with a number of previous studies 
showing that CVB attach to mononuclear phagocytes 
but that these cells are not permissive for virus 
replication (7). We did not observe differences in the 
response to viable or inactivated CVB or PV (Fig. 3), 
which indeed indicates that the cytokine response
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against virus is not dependent on viral replication. 
Furthermore, pre-incubation with virus did not affect 
the ability of lymphocytes to respond against the 
control antigen tetanus toxoid or to mitogen activation 
indicating that exposure to enterovirus does not 
interfere with the cytokine secreting capacity of the 
cells. In the present study, we investigated cytokine 
responses in isolated peripheral leukocytes which may 
limitate an extrapolation to the local response.
Enteroviruses have been associated with the 
development of type 1 diabetes. A hallmark in the 
development of diabetes mellitus is a massive 
infiltration in the pancreatic islet cells by lymphocytes 
and monocytes. Animal models support that the pro- 
inflammatory cytokines play an important role in the 
pathophysiology of type 1 diabetes mellitus. These 
cytokines are involved in activation of cells of the 
immune system, thereby potentiating an effective 
immune response in the target organ or draining lymph 
nodes (8). Furthermore, it has been well documented 
that cytokines like IL-1ß, TNF-x, and IFN-y by 
themselves are toxic for pancreatic -cells (9) and these 
cytokines have been suggested as possible inducers of 
ß-cell antigens. In addition, evidence is emerging that 
modulation of the immune response towards Th1 
responses plays a critical role in progression of the 
autoimmune disease (10,11), whereas IL-4 is decreased 
in in diabetes patients (12). Exposure of human PBMC 
to enteroviruses resulted in the production of the Th1 
cytokines IL-2, IFN-y but not in significant levels of IL- 
4 (Fig. 4), although considerable variation in the 
cytokine levels was observed in the individual donors. 
Production of the Th2 cytokine IL-10 was observed in 
all tested samples when exposed to enteroviruses (Fig. 
4). IL-10 plays a role in the activation of B 
lymphocytes to produce antibodies. Furthermore, 
expression of IL-10 in the pancreatic cells breaks 
tolerance and induces tissue-specific autoimmunity in 
non-obese diabetes (NOD) mice (13).
Recently, it was shown that CVB can activate a 
subset of existing autoreactive T-cells, thereby causing 
diabetes in transgenic NOD mice (14). This proces 
required a local infection and might be acomplished by 
cytokines. Since many CVB-like enteroviruses have a 
tropism for the pancreas (15), it can be envisaged that a
A IL-1 ß (pg/ml)
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Figure 3. Cytokine production by enterovirus-exposed PBMC.
Human PBMC were exposed to infectious (CVB, PV) and 
inactivated (iCVB, iPV) virus preparations from CVB4 and 
poliovirus. After 24 h. of incubation, culture supernatants were 
harvested, and the content of IL-1ß (A) and TNF-a (B) was 
determined. Values are the mean ± SD of 4 independent 
experiments.
local CVB infection may result in the production of 
cytokines by resident macrophages and lymphocytes 
recruited to the islets, and that the toxic effects of 
cytokines released during viral infection may cause 
focal -cell damage resulting in presentation of -cell 
specific antigens by antigen-presenting cells. The 
presence of self-antigens triggers potential 
autoimmune cells and, in the absence of efficient 
immune regulatory mechanisms, this consequently may 
result in the development of ß-cell specific 
autoreactivity. Several genetic and other environmental 
factors may determine the outcome of a viral infection 
in individual persons. The present findings demonstrate 
that exposure to enterovirus induces production of 
cytokines which may contribute to the development of 
autoimmunity.
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Figure 4. Production of T-helper cytokines by virus-exposed PBMC. PBMC were exposed to infectious and inactivated (iCVB, iPV) 
virus preparations from CVB4 and poliovirus. After 6 days of incubation, culture supernatants were harvested, and the content of IL-2 (A), 
IFN-y (B), IL-4 (C), and IL-10 (D) was determined. Values are the mean ± SD of 2 independent experiments using PBMC from 9 
different donors. Spontaneous release of cytokines is represented by the medium control response, and positive control responses by 
tetanus toxoid by tetanus toxoid (TT).
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Coxsackie B viruses (CVB) may cause pancreatitis and are associated with the development of 
type 1 diabetes mellitus. They can infect pancreatic cells and cause initial damage in the pancreas. 
Toxic and inflammatory mediators induced during infection may enroll deleterious effects to the 
insulin-producing pancreatic ß-cells, and may play a role in the regulation of (auto-) immune 
responses. Ductal cells are closely associated with the islets of Langerhans and are a potential 
source of inflammatory mediators. In this study, the effects of coxsackie B4 infection on the 
production of nitric oxide and inflammatory cytokines in human pancreatic ductal cells was 
studied. CVB4 infection induced significant amounts of TNF-a in a dose and time dependent 
manner that was correlated to the cytopathic effects of the virus. The production of TNF-a was 
induced at a pre-transcriptional level and was inhibited by nicotinamide, a drug that is used in 
clinical trials to improve -cell function in (pre-) diabetes patients. Viral infection and endogenous 
production of TNF- did not result in induction of nitric oxide, IL-1 , or IFN- in the ductal cells. 
These findings indicate that CVB infections are a potent inducer of TNF-a in the pancreas, which 
may play a role in the development of pancreatitis and/or type 1 diabetes mellitus.
Coxsackie B viruses (CVB) are associated with type 1 
diabetes mellitus and there is well-documented clinical 
evidence linking coxsackieviruses to the development 
of both pancreatitis and type 1 diabetes in humans 
(1,2). Type 1 diabetes mellitus is characterized by a 
progressive loss of insulin producing -cells and by 
autoimmune responses directed against multiple 
components of islet cells and their products. ß-cell 
destruction is often preceded by insulitis, a massive 
infiltration of lymphocytes in the islets. The 
pathophysiologic role of enteroviruses in the disease 
process has still not been elucidated. The isolation of 
CVB4 from the pancreas of a diabetic patient suggested 
that local infection of pancreatic cells may result in - 
cell destruction (3). Enteroviruses of different 
taxonomical groups are known to infect and replicate in 
(murine) pancreatic islet cells in vitro (4,5). Primary 
cultures of human pancreatic islet cells are also 
permissive for enterovirus infections, although this 
tropism appears to be strain dependent (6,7). However, 
destruction of a limited number of ß-cells by a cytolytic 
viral infection does not explain the progressive loss of
the majority of ß-cells in type 1 diabetes mellitus and 
induction of autoimmune responses. Thus, a primary ß- 
cell infection is not likely to explain the development of 
autoimmune diabetes. However, an initial viral 
infection in the pancreas can initiate a number of cell 
biological and immunological responses, which, in 
susceptible patients ultimately may lead to a 
dysregulation of the immunologic responses and 
induction of autoimmunity. Inflammatory mediators 
and cytokines are important factors in this process (8). 
Cytokines enhance and sustain inflammation and are 
toxic to ß-cells (9).
An infection does not necessarily have to start in the - 
cells themselves. Infected cells around the islets can 
initiate insulitis. Inflammatory mediators produced by 
these cells may affect bystander -cells by being 
directly toxic to -cells or influencing the local immune 
response. Ductal cells are closely associated with 
human -cells. They are a potential source of nitric 
oxide (NO) in human islets (10) and may play an 
important role in the pathogenic process leading to
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inflammation and pancreatitis. Ductal cells may form 
the portal of entrance of the exocrine and endocrine 
pancreas for enteroviruses entering the body via the 
intestinal tract. In this study, we infected primary 
cultures of human pancreatic ductal cells with CVB4 
and investigated the production of nitric oxide (NO) 
and inflammatory cytokines by these cells.
M a t e r ia l s  a n d  m e t h o d s
Viruses. A  clinical CVB4 isolate was used in this study to 
infect human islet cell cultures. Virus stocks were produced 
in buffalo green monkey kidney (BGM) cells. The cells were 
grown in minimal essential medium (MEM) supplemented 
with 10% fetal bovine serum (FBS). After complete 
cytopathic effect was reached, virus was released by three 
cycles o f freezing and thawing. Cellular membranes were 
removed by centrifugation at 15,000 g and virus was purified 
by high speed centrifugation on a 30% sucrose cushion. This 
procedure resulted in a viral yield o f more than 109 
TCID5 0 /ml (50% tissue culture infective dose). For 
inactivation o f the virus, virus preparations were exposed to 
U V  light at a distance o f 20 cm (UV dose =250 mJ) in a GS 
Genelinker (BioRad, Laboratories) and the loss o f infectivity 
was ascertained.
Islet cell isolation and culture conditions. Human 
pancreatic ductal cells were isolated from pancreases 
obtained from adult heart-beating organ donors. The organs 
were procured by European hospitals affiliated with the 
Eurotransplant Foundation (Leiden, the Netherlands) and 
with BETA-Cell Transplant, a multicenter program on -cell 
transplantation in diabetes. They were processed at the 
Central Unit in Brussels, as previously described (11). Ductal 
cell fractions were cultured in Hams F10 supplemented with
2 mM L-glutamine, 0.075 grams/liter penicillin, 0.1 
grams/liter streptomycin, 7.5 mM glucose, and 10 grams/ liter 
charcoal-treated BSA (Boehringer Mannheim, Mannheim, 
Germany). The ductal cell fraction consisted o f > 90% 
cytokeratin 19 (CK19) positive ductal cells and 5% endocrine 
cells. Addition of 10% FBS was needed for cell attachment 
and spreading o f the ductal cells. One day before infection 
with virus, serum was removed from the cultures.
-cell viability assay. The percentage of viable, necrotic, or 
apoptotic cells after virus infection was assessed 2 to 48 
hours post infection. Ductal cells were infected with CVB4 at 
a multiplicity o f infection (MOI) o f 5. The cytotoxicity test is 
based on fluorescent staining o f nuclei with Hoechst stain 
33342 (HO) and propidium iodide (PI) (12). Apoptotic cells 
were detected by their fragmented nuclei. The results are 
expressed as necrosis and apoptosis index. The necrosis 
index was calculated with the following formula: 
necrosis index =
%  necrotic cells sample - % necrotic cells control x 100% 
100- % necrotic cells control
The apoptosis index was obtained by replacing the 
percentage o f necrotic cells by the percentage o f apoptotic 
cells.
Virus replication in ductal cells. Single cycle growth 
curves were determined by infecting 20.000 pancreatic ductal 
cells with the virus at an MOI o f 5 and viruses were yielded 
at different time points after infection. Virus yields were 
titrated in BGM cells in 96 well plates. TCID50 values were 
calculated according to the method o f Reed and Meunch
(13).
Cytokine measurements. A  double-antibody sandwich 
enzyme-linked immunosorbent assay (Pelikine CompactTM 
human cytokine ELISA kit, CLB, Amsterdam, The 
Netherlands) was used to measure human IL-1ß, TNFkx, and 
IFN-y . The detection limit for IL-1ß was 0.4 pg/ml, for TNF- 
1 pg/ml, and for IFN- 2 pg/ml. Extinction was measured 
in an ELISA reader (Merlin Titertek Multiskan, Rotterdam, 
the Netherlands) at 450 nm according to the instructions of  
the manufacturer. To minimize analytical errors the samples 
were analyzed in triplicate.
Detection of N O  and inducible nitric oxide synthase 
(iNOS) activity. The formation o f NO was measured as 
described by Green et al. (14). In each individual 
experiment, aliquots o f  supernatants (0.1 ml) from ductal 
cells were incubated and mixed with the same amount of 
Greiss reagent (0.1% naphtyl-ethylenediamine dihdrochloride 
[Sigma] in distilled water and 1% sulfanilamide [Sigma] in 
5% phosphoric acide [vol/vol]. Subsequently this mixture 
was incubated for 20 minutes at 60oC, and the optical density 
at 546 nm was measured in a spectrophotometer. The 
production o f iNOS was determined on western blot as 
described (Hoorens, JCI 1996). The ductal cells were left 
untreated, were infected with CVB4 (MOI 5), or exposed to a 
combination o f the cytokines IL-1ß (100 IU recombinant; 
Genzyme, Cambridge,MA), TNF- (50 IU recombinant 
Innogenetics, Gent, Belgium) and IFN-y (1000 IU 
recombinant, Genzyme), or 3162 (1.2.3.4-oxatriazolium, 5- 
a m in o -3 -(3 ,4 -d ic h lo r o p h e n y l)  ch lo r id e  (G E A )  
(Alexis,Nottigham, United Kingdom), a donor o f exogenous 
NO. In addition, cells were cultured with 1 mM L-N-methyl- 
arginine (L-NMA) (Sigma).
R e s u l t s
Infection with CVB4 induces TNF- in ductal cells.
To study whether infection with a CVB induces 
production of the proinflammatory cytokines IL-1ß, 
TNF - and IFN- , primary cultures of human ductal 
cells were infected with CVB4 and the release of 
cytokines was measured at indicated time points post 
infection (Fig. 1). Infection with CVB4 resulted in the 
production of significant amounts of TNF-a, but IL-1ß 
and IFN-y were not detectable. CVB4-infected ductal
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Figure 1. CVB4 induces TNF-a production in human pancreatic ductal cells. (A): Time course of TNF-a production. Cells (2 x105/ml) 
were exposed to CVB4 at different MOIs. TNF-a production at indicated time points was measured in the cell supernatants in triplicate. 
Values represent the concentration of TNF- (pg/ml) measured in cultures from 5 different donors. (B): Replication of CVB4 in human 
pancreatic ductal cells. Ductal cells were infected with CVB4 at an MOI of 5. At indicated time points, the viral titer was determined as 
detailed in the text. Values are the mean (± standard deviation) of 6 donors. (C): Cytopathic effects of CVB4 in pancreatic ductal cells 
expressed as the percentage of necrotic cells. Cells were infected with CVB4 at an MOI of 5. At indicated time points the percentage of 
apoptotic and necrotic cells was scored as related to non-infected cells. Values represent the mean index (± standard deviation) of 5 
donors.
Figure 2. TNF-a production requires replicating virus. (A) Ductal cells were exposed to infectious CVB4 (MOI 5), UV-inactivated 
CVB4 (MOI 5) and not infected. TNF-a induction was meassured 48 hours post infection by ELISA. Values are the mean (± standard 
deviation) of 2 donors. (B) poly I:C induces high amounts of TNF-a in a concentration dependent way. Values are representative for 3 
independent experiments.
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cells produced TNF- in a dose-dependent manner 
(Fig. 1A). For the same time points, viral replication 
and the cytopathic effects of enterovirus infection were 
investigated for the ductal cells. Infection of ductal cells 
resulted in a relatively low, but significant level of 
replication of the virus (Fig. 1B). The time course of 
TNF - production was related to the time course of 
virus induced cytopathic effects (Fig. 1C). Only low 
percentages of apoptotic cells could be detected 
(<10%). Apoptosis thus appears to play a minor role in 
the mechanism of CVB-induced damage.
TNF- production is dependent on replicating 
virus. To investigate whether TNF- production is 
induced by exposure of the cells to virus, or requires an 
infectious cycle, cytokine production was determined in 
CVB4-infected cells, cells exposed to inactivated 
CVB4, and mock-infected ductal cells. Inactivated 
virus did not induce significant amounts of TNF- , 
indicating that viral replication is needed for induction 
of TNF-x (Fig. 2A). High levels of TNF-x were also 
produced by poly I:C, a synthetic dsRNA, which 
mimics the viral replication intermediate (Fig. 2B). 
This suggests that viral replication, rather than the 
presence of specific viral proteins is responsible for the 
induction of TNF-a. Furthermore, it implies that TNF-a 
production in infected ductal cells is not CVB4 specific 
but might also be induced by infections with other 
enteroviruses which have a tropism for the pancreas.
Virally-induced TNF- is inhibited by nicotinamide.
Treatment with high doses of nicotinamide 
(niacinamide, vitamin B3) protects islet cells against 
cytotoxic actions (15). It has major regulatory effects 
on cytokine gene transcription. CVB4 infected ductal 
cells were pre-treated with increasing doses of 
nicotinamide and were analyzed for the effect on TNF- 
production. TNF- production was blocked by 
nicotinamide in a concentration dependent way (Fig. 
3A). To investigate whether this inhibition could be 
ascribed to effects on the virus, growth curves were 
performed in the presence and absence of nicotinamide. 
No difference in viral growth was observed (Fig 3B). 
TNF -a inhibition could also not be ascribed to toxic 
effects on the ductal cells since pretreatment of ductal 
cells with nicotinamide had no effect on cell viability 
(data not shown). This indicates that nicotinamide 
inhibits TNF- production by interference with TNF-
gene transcription and implies that CVB4-induced 
TNF- production is induced at a pre-transcriptional 
level.
IFN- inhibits CVB4 induced TNF- production by 
interfering with the viral replication. IFN- is an 
important mediator in the anti-viral defense 
mechanisms of the host and plays a role in the 
regulation of the immune response. Whereas IFN-y 
alone has no effect on TNF- production, it enhances 
TNF- induced by poly I:C in a dose dependent way 
(data not shown). However, addition of IFN-y to 
CVB4-infected dutal cells resulted in a decreased TNF- 
a production (Fig. 4). Viral growth curves 
demonstrated a decrease of viral replication in the 
presence of IFN-y (Fig. 3B). Thus, the inhibiting effect 
of IFN- on TNF- is probably due to the anti-viral 
effects of IFN- .
CVB4 infection does not induce NO in infected 
ductal cells. The production of TNF-x by virus- 
infected cells may lead to additional transcription of 
inducible nitric oxide synthase and NO formation (16, 
10, 17). Recently, it has been shown that enteroviruses 
can induce NO in Hela cells in vitro. In high quantities 
NO functions as an endogenous anti-viral defense 
mechanism and limits viral replication (18). NO is toxic 
for -cells and may play a role in -cell destruction as 
mediator in bystander killing (19). In order to study 
whether CVB4 induces NO in ductal cells, primary 
cultures of ductal cells were infected with increasing 
doses of virus and NO and iNOS were measured. As a 
positive control, the cells were exposed to a mixture of 
IL-1ß (100 IU), TNF-a (50 IU) and IFN-y (1000 IU). 
These cytokines induced a significant production of 
NO (Table 1), indicating that ductal cells are a potential 
source of NO. The cytokines also induced the inducible 
enzyme iNOS, which is involved in endogenous 
production of NO (data not shown). Furthermore, the 
production of NO was inhibited by incubation with 1 
mM L-NMA, an NO inhibitor, which also indicates 
that NO was endogenously produced. However, we did 
not detect significant levels of NO in the supernatants 
of CVB4 infected cells (Table 1). This suggests that 
NO does not play a role in the cellular anti-viral 
defense against CVB4 infections in ductal cells.
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Figure 3. (A): TNF-a production induced by CVB4 infection is inhibited by nicotinamide. Ductal cell cultures were left untreated, or pre­
incubated with increasing concentrations of nicotinamide. Subsequently, cells were infected with CVB4 at an MOI of 5. At several time 
points post infection the accumulation of TNF-a in the supernatants was assayed. Values are the mean of 5 donors, performed in 
triplicate. (B). Nicotinamide does not affect viral growth in ductal cells, whereas pretreatment with IFN- decreases viral yield. Ductal 
cells were either left untreated, pretreated with nicotinamide (5mM) or exposed to IFN-y (1000 IU), and subsequently infected with CVB4 
at an MOI of 1. The viral titer was determined at indicated time points. Values are the mean of 4 donors, performed in 4 independent 
experiments.
hours post infection
Figure 4. TNF- production by CVB4 infection is inhibited by
IFN . Cells were exposed to increasing concentrations of IFN 
and infected with CVB4 at an MOI of 5. At several time points 
post infection the amount of TNF-a in the supernatants was 
assayed. Values are the mean of 5 donors, performed in triplicate.
L-NMA NO production 
(nM)
cell viability 
(% viable cells)
mock 1.2 ± 0.6 74 ± 12
mock 2mM 1.2 ± 0.8 78 ± 13
CVB4 1.0 ± 0.7 41 ± 23
CVB4 2mM 1.1 ± 0.3 54 ± 28
cytokines* 5.7 ± 2.8 § 64 ± 4
cytokines* 2mM 1.3 ± 0.6 J 68 ± 18
GEA 4.2 ± 0.4 § 74
GEA 2mM 4.6 ± 0.5 § 62
Table 1. CVB4 does not induce NO in human pancreatic ductal 
cells. Cells were left untreated or pre-incubated for 4 h with 2mM 
L-NMA. Subsequently, cells were infected with CVB4 (MOI 5); 
mock infected, exposed to a mixture of 1000 IU/ml TNF-a, 50 
IU/ml IL-1ß, and 1000 IU/ml IFN-y (*), or treated with the NO 
donor GEA (20 mM). The production of NO was measuredat 48 
hours. §, significant different values from untreated cells, J 
significant different value from cytokine induced NO. Viability of 
the cells was determined by HO-PI staining as detailed in the text. 
Values are the mean of 4 independent donors.
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DISCUSSION
In this study, we showed that coxsackieviruses not only 
replicate in pancreatic ductal cells and kill the cells by 
their lytic life cycle, but the virus also induces TNF-a 
production during infection. The induction of TNF-x is 
time- and dose- dependent and requires viral 
replication. As far as we know, this is the first report of 
endogenously produced TNF- by enterovirus infected 
non-immune cells. The induction of inflammatory 
cytokines by enteroviruses in immune competent cells 
follows a different mechanism since it does not require 
infection of the leukocytes and is a replication- 
independent process (20).
Inflammatory cytokines are important mediators 
during pancreatitis and play a role in the development 
of type 1 diabetes mellitus (8). Production of pro- 
inflammatory cytokines in the pancreas attracts 
immune cells to the site of infection and leads to the 
initiation of insulitis, a process that often precedes the 
clinical stage of type 1 diabetes. The role of TNF-a 
especially, in the development of type 1 diabetes has 
obtained much interest. TNF-x plasma levels are 
increased in type 1-diabetes patients and TNF- is 
associated with metabolic control (21). Furthermore, 
TNF micro satellite polyphmorphisms contribute to the 
susceptibility of type 1 diabetes (22). In the mouse 
model of diabetes mellitus, TNF- has the ability to 
accelerate autoimmune diabetes when administered 
systemically (23) and neonatal TNF- expression 
promotes autoimmune responses of CD4+ and CD8+ T- 
cells (24). However, when TNF-x is constitutively 
expressed in the pancreas under the control of an 
insulin promoter, transgenic mice are prevented from - 
cell directed autoimmunity (25). Several pathogenic 
roles for TNF-x have been hypothesized. It may be 
toxic to the insulin producing -cells by potentiating - 
cell death via death signaling mediated apoptosis 
and/or functional impairment of ß-cells (26). TNF-a 
may also have important regulatory functions in the 
induction or prevention of autoimmunity. TNF- is 
involved in the transition from benign to pernicious 
insulitis in autoimmune diabetes (27). It has been 
speculated that overexpression of TNF- results in a 
deviation of the balanced Th1 and Th2 responsiveness 
of the immune system (28). TNF- may shift the 
immune response towards cellular reactivity, which is 
correlated with a rapid and progressive development of 
autoimmune diabetes (29). In this study, we
demonstrated that CVB infections can function as a 
cause of increased levels of TNF- in the pancreas.
Classically, enteroviral replication is believed to 
cause cellular necrosis by destruction of the plasma 
membrane and disruption of the cytoskeleton. It also 
induces a shut off of host cell protein synthesis and 
disruption of the Golgi complex (30). Although 
enteroviruses cause a rapid death of their host cells, 
numerous processes take place aimed either to facilitate 
viral replication or to induce host defense mechanisms 
against the invading virus. In vitro studies in Hela cells 
showed that host cell protein shut off and abrogation of 
the excretory pathway is induced within 4-6 hours post 
infection and the infected cells are lysed within 8 hours 
due to the cytopathic activity of the virus (30). 
Replication in ductal cells required a longer time span 
and resulted in a 2-3 log lower yield of viral progeny as 
compared with Hela cells. Thus, in primary cultures of 
human ductal cells the time course of viral cytolysis 
seems to be extended, which gives the infected cells the 
opportunity to activate anti-viral defense mechanisms 
resulting in de novo production of cytokines. This 
implies that transcription and translation still take place 
in ductal cells infected with a cytolytic CVB4.
During enteroviral infection, the host ennumerate a 
variety of antiviral mechanisms to control the viral 
infection (31). Upon viral infection, host cells produce 
nitric oxide, which, when produced in large amounts, 
limits viral production (18). In addition to endogenous 
cellular defense mechanisms, the production of IFN- 
by immune cells leads to increased surveillance over 
infected cells by the immune system and clearance of a 
viral infection. IFN-y has been shown to protect mice 
from lethal coxsackievirus-induced pancreatitis by 
transgenic expression in the pancreas (32). It was 
shown that IFN-y activates macrophages before and 
after infection and inhibits viral replication in vivo. In 
our study, IFN-y decreases viral replication 10 to 100 
fold in the absence of cells of the immune system. This 
suggests that the decrease of TNF- is excerted by the 
inhibition of viral replication.
Nicotinamide is a vitamin B3 that has been shown 
to protect islet cells against cytotoxic actions and 
improves ß-cell function in vitro. Nicotinamide inhibits 
poly ADP-ribose polymerase (PARP). Suppression of 
PARP activity by nicotinamide has regulatory effects 
on cytokine gene expression and controls early steps of 
apoptosis. As a consequence, cell death pathways and 
gene expression patterns are modified, leading to
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improved -cell survival and an altered immune 
regulatory balance (15,33). Nicotinamide is being used 
in clinical trials to improve cell function in diabetes and 
pre-diabetes patients. We demonstrated that 
nicotinamide inhibits TNF- production by ductal cells 
in a dose-dependent manner, when infected with an 
enterovirus. This inhibition could not be ascribed to 
effects of nicotinamide on virus replication but may 
rather result from interference with TNF transcription. 
These results indicate that in the case of an enterovirus 
infection in the pancreas, nicotinamide may have 
additional (beneficial?) effects for the pathogenesis of 
type 1 diabetes mellitus by reducing the amount of 
produced TNF- .
The inhibition of TNF- production by 
nicotinamide indicates that the mechanism of TNF- 
induction by a viral infection takes place at a pre- 
transcriptional level and requires transcription and 
translation. This is supported by experiments using 
translation and transcription inhibitors. The production 
of TNF-x by both CVB4 and poly I:C could be 
inhibited by cyclohexamide and actinomycin D in a 
dose dependent way (data not shown). Furthermore, 
staurosporin, a broad range kinase inhibitor also 
reduced TNF- production (data not shown) indicating 
that kinase signaling pathways are involved in the 
induction of TNF-a.
In this study, evidence is provided for interference 
of CVB4 infection with the transcription of TNF- 
resulting in an increased TNF- production. The 
mechanism, however, is not clear. It is possible that 
viral products directly interfere with transcription via 
activation of the kinase signalling pathways leading to 
gene transcription (34). It cannot be excluded, however, 
that TNF- transcription is induced by intermediate 
production of interferons. Small amounts of IFN-ß 
were detected in cultures of infected ductal cells. 
Furthermore, exposure with increasing amounts of IFN- 
showed a dose dependent production of TNF- in 
ductal cells (data not shown), indicating that IFN-ß is a 
potent inducer of TNF- in ductal cells.
Based on our findings, we hypothesize that 
enterovirus infections can play a role in the 
development of type 1 diabetes mellitus by induction of 
enhanced levels of TNF- in the pancreas, which may 
have toxic effects on the bystander -cells and may 
cause a distortion of the immune regulatory balance 
resulting in autoimmunity in pre-disposed individuals. 
This study provides an alternative mechanism for the
involvement of enterovirus infections in the 
development of type 1 diabetes mellitus by endogenous 
production of TNF- in virally infected cells.
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S u m m a r y  a n d  G e n e r a l  D is c u s s io n
Type 1 diabetes mellitus is a chronic multifactorial 
disease in which the insulin producing -cells in the 
pancreas are targets of destructive autoimmune 
processes. The role of enteroviruses in the etiology of 
type 1 diabetes mellitus has been suggested in a number 
of studies and recent prospective studies have 
emphasised on the etiologic role of enteroviruses in the 
disease process. Extending these correlations to identify 
pathological mechanisms by which -cell destruction is 
caused and autoimmune processes are triggered by 
enteroviruses, however, has proven difficult. Several 
mechanisms have been proposed including direct and 
indirect pathways in the disease process (chapter 1). 
First, the virus may cause -cell damage by its direct 
cytopathic effect on the cells. A local viral infection 
may also cause bystander effects on -cells by 
induction of cytokines and other toxic mediators. 
Alternatively, it has been postulated that an 
immunological cross-reaction against the viral protein 
2C and the islet cell antigen glutamic acid 
decarboxylase (GAD65) might be implicated in 
autoimmune induction. Finally, it has been suggested 
that viral infections play a role in modulation of the 
immune system which, in susceptible patients, may 
result in loss of tolerance and activation of autoreactive 
T-cells against islet cell antigens. None of these, 
however, has been proven exclusively neither 
conclusively to influence the pathogenesis of human 
type 1 DM.
Molecular mimicry in human diabetes.
The sequence homology between the enteroviral 
protein 2C and the -cell antigen GAD65 (PEVKEK) 
was the basis for the hypothesis of molecular mimicry, 
i.e. a cross-reactive immune response directed against 
these antigens. In human diabetes, GAD65 is one of the 
major and early autoantigens. It has been reported that 
a temporal relationship exists between infection with 
enteroviruses and development of antibodies against 
islet cell antigens of which GAD65 is a major 
component (1). This suggests that molecular mimicry 
might be relevant in the development of autoimmunity. 
In chapter 2, we showed that the p2C sequence with
homology to GAD65 is not only present in CVB4, but is 
highly conserved in the CVB-like group of 
enteroviruses, including the major group of ECHO 
viruses. The high degree of conservation of the 
PEVKEK motif in enteroviruses suggests that the 
possibility of inducing mimicry can be ascribed to a 
broad group of these highly prevalent viruses. 
Moreover, the existence of mimicry sequences in 
nature is exceedingly common (2), the more since it is 
known that mimicry does not require identical 
sequence similarities but can result from rather 
promiscuous amino acid sequences (3). This implicates 
that mimicry might be a common phenomenon that 
must be restricted and /or regulated by other (genetic) 
factors. Besides regulation by regulatory cells of the 
immune system, determinants that are involved in 
mimicry consist of HLA molecules, which regulate 
selectively antigen presentation to the immune system 
and which form a primary genetic restriction for 
molecular mimicry. We and others have demonstrated 
that the mimicry peptides can bind to HLA-DR3 
(chapter 2) and HLA-DQ8 molecules, alleles that have 
been associated with development of human type I 
diabetes (4). These alleles may play a role in the 
disease process by presenting peptides which induce T- 
cell cross-reaction and subsequent autoimmunity .
A GAD65 peptide exhibiting the PEVKEK sequence 
homology with CVB4 p2C appeared to be one of the 
dominant epitopes on GAD65 that are recognised by 
autoreactive T-cells in type 1diabetes mellitus patients. 
However, T-cell responses to GAD65 seemed not to be 
specific for diabetes patients but can also be found in 
healthy unrelated controls (5). Recent findings 
demonstrated that T-cell responses to enteroviruses and 
p2C are more frequent in diabetes patients with 
established clinical symptoms than in controls (6), but 
this was not found in recent onset patients (6,7). At a 
clonal level, T-cell cross-reactivity between GAD65 and 
p2C has never been demonstrated. On the contrary, 
GAD65-specific T-cells obtained from patients at 
clinical onset of diabetes mellitus that were cultured in 
the presence of both GAD65-derived and p2C-derived 
homologous peptides did not cross-react, although 
reactivity against either one or the other peptide was
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detectable (B.O. Roep, personal communication). Until 
now, no final prove for the hypothesis of molecular 
mimicry exists in human diabetes.
Apart from studies on cellular molecular mimicry, 
several studies have been performed to investigate a 
possible antibody cross-reactivity against the 
homologous sequence of GAD65 and p2C. In animal 
studies, it has been shown that antibodies induced by 
p2C peptides cross-react with the homologous GAD65 
peptides (8), but the relevance in human diabetes could 
not be proven. In diabetes patients, no correlation of 
antibodies against GAD65 and p2C was observed (9). In 
chapter 3, we showed that antibodies against the 
enterovirus p2C are very common in the population, 
while antibodies against GAD65 are highly specific for 
(pre-) diabetes patients. Thus, the high prevalence of 
anti-p2C antibodies suggests that these antibodies (in 
general) do not cross-react with GAD65.
Cytopathic effects on ß-cells.
In chapter 4, putative pathogenic pathways of 
enterovirus-induced diabetes were investigated in a 
child who acutely developed insulin dependency during 
a severe systemic infection with echovirus type 9 
(EV9). The possibility of cytolytic effects of 
enteroviruses on -cells was investigated by infecting 
cultures of human islet cells with enteroviruses. The 
clinical isolate of EV9, obtained from the patient did 
not grow in the human islets, whereas a clinical CVB4 
isolate and the laboratory CVB3 strain (Nancy) did. 
The different receptors used by CVB and EV might 
explain the difference in -cell tropism and infectivity. 
Thus, although enteroviruses can cause -cell 
destruction via a direct, non-autoimmune-mediated 
pathway, in the patient, there was no evidence for a 
direct cytolytic action of the virus on -cells. 
Furthermore, the hypothesis of molecular mimicry was 
investigated in the child. Although the viral protein 2C 
exhibited a sequence similarity with GAD65 and HLA- 
based prerequisites were met, no cross-reactive T-cell 
responses were detected against the two proteins. The 
patient did not develop GAD65 antibodies either. The 
absence of evidence for a direct cytopathic action or an 
indirect effect through molecular mimicry suggests a 
different indirect pathway through which the
enterovirus has caused diabetes.
Bystander effects of viral infections
Infection with a pancreotropic enterovirus and 
subsequent local inflammation causes local tissue 
damage. During inflammation, cytokines and free 
radicals produced by macrophages and activated T- 
cells are released. Such cytokines have been suggested 
to play a role in the process of -cell destruction. In 
chapter 5, it is described that CVB induces strong 
inflammatory reactions with release of TNF- and IL- 
1 from mononuclear cells. Thus, during infection and 
inflammation in the pancreas, -cell- toxic cytokines 
might be produced by infiltrating monocytes and 
lymphocytes.
Many viruses can cause a modulation of the 
immune response by directing the immune response 
towards Th1 pathways (IL-2, IFN- and TNF- 
production) and meanwhile suppressing the Th2 
pathway (IL-4 and IL-10 secretion). A shift of the 
immune response towards Th1 responses has been 
associated with a rapid development of diabetes (10). 
We showed that exposure of isolated PBMC to CVB 
resulted in the production of IL-2, IFN-y, and IL-10, 
whereas IL-4 could not be detected (chapter 5). The 
induction of IL-2 and IFN-y and lack of IL-4 after CVB 
stimulation might skew the immune response towards 
autoaggressive Th1 like responses. Thus, exposure of 
enterovirus to immuno competent cells induces the 
production of cytokines, which may contribute to the 
development of autoimmunity.
It is not known whether enteroviruses modulate the 
immune response in patients with type 1 DM. Several 
genetic and environmental factors may determine the 
outcome of a viral infection in individual persons. It 
remains to be investigated whether enterovirus-induced 
cytokines play a role in the disease process in patients.
The production of cytokines which are involved in 
ß-cell damage and/or survival is not restricted to cells 
of the immune system, but infection of local pancreatic 
tissue cells may induce cytokines by the infected cells 
as well. In chapter 6, it is demonstrated that infection 
of human ductal cells, which are closely associated 
with the islets of Langerhans, results in the production 
of TNF-x. This CVB-induced TNF-a production can
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completely be blocked by nicotinamide, a drug that has 
been used in clinical trials to prevent the progression to 
type 1 diabetes mellitus.
The exact role of TNF-x in the pancreas is not clear, 
but there is increasing evidence that TNF-a plays a 
role in the susceptibility and/or development of type 1
diabetes mellitus. TNF- gene polymorphisms and 
increased plasma levels are associated with the 
development of type 1 diabetes (11,12). Furthermore, it 
has been shown that TNF- is involved in the transition 
from benign to pernicious insulitis in autoimmune 
diabetes (13).
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Figure 1. Schematic view of ß-cell decline during the process of type 1 diabetes mellitus. Enteroviral infections may play a role in the 
destruction of ß-cells as initiating event (a), may be involved in the pre-diabetic phase as direct or in-direct contributors to the ß-cell 
damage (b), and/or may cause the final trigger in a rapid decline of ß-cell mass resulting in insulin dependency (c). The dashed line 
represent the treshold level of ß-cells, neccesary to maintain the glucose homeostasis.
Involvement of enteroviruses in the pathogenesis of 
type 1 diabetes mellitus
There is increasing evidence supporting a causal 
relationship between enteroviruses and type 1 diabetes 
mellitus (15). It can not be excluded, however, that 
patients with type 1 diabetes mellitus or patients at risk, 
are more susceptible for viral infections and are more 
frequently infected and thus show increased immune 
activity to enterovirus. Recent insights in autoimmune 
processes in type 1 diabetes mellitus are suggestive of 
impaired immunoregulatory functions in the patients 
(16,17). It is not known whether this is caused by viral 
infections, or influences the suseptibility for enteroviral
infections.
Though enteroviruses are supposed to be one of the 
most important environmental factors, they are not the 
exclusive factor involved in the disease process. Type 1 
diabetes mellitus is thought to result from a complex of 
genetic, immunologic and environmental factors and 
the etiology of the disease may vary between 
individuals. The role of enteroviruses may be seen as a 
triggering event and limited to a subset of patients. The 
models discussed above reflect different mechanisms 
that do not necessarily exclude each other. Several 
pathways may contribute to the development of 
diabetes and may act either independently or 
concurringly in the destruction of pancreatic -cells
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(14). Enteroviruses may play a role at several stages of 
the development of type 1 diabetes mellitus. They may 
play a role in initiation, acceleration and precipitation 
of the disease as supported by several lines of 
epidemiological evidence. Figure 1 summarises the 
possible temporal involvement of enteroviral infections 
in the course of diabetes development. It is proposed 
that the frequency of infections and dissemination of 
enteroviruses to the pancreas are important factors in 
determining the pathogenic role of the virus.
The fact that type 1 diabetes mellitus often has a 
long subclinical phase during which the important 
pathogenic processes take place has hampered research 
substantially. Longitudinal prospective studies starting 
with birth cohorts are the designated way to investigate 
the precise pathogenic mechanism of enteroviruses at 
initiation and during the development of type 1 diabetes 
mellitus. In such studies, the interference of virus 
infections with the immune system of patients with 
type 1 DM, or subjects at risk, needs to be further 
investigated by analysis of the cytokine profiles and by 
investigating the T-cell repertoires after viral infection 
in these patients.
Final considerations
Type 1 diabetes mellitus is a health problem associated 
with considerable morbidity, reduced life expectancy 
and significant health costs. Until now, no curative 
prospects are available besides -cell transplantation, 
which is only recommended for patients with serious 
secondary complications since transplantation is an 
intervention with life-long medication. Although 
promising results have been obtained with 
transplantation, delay of clinical outcome or even 
prevention of the disease is a more desirable goal. A 
better understanding of the role of enteroviruses in the 
disease process may help to device strategies to delay 
or even prevent onset of type 1 diabetes mellitus, 
possibly by vaccination against diabetes-associated 
enterovirus strains.
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Samenvatting
Type 1 diabetes mellitus is een chronische 
multifactoriële ziekte waarbij de insuline producerende 
ß-cellen het doelwit zijn van autoimuniteit, een proces 
waarbij het immuun systeem zich tegen lichaamseigen 
cellen richt. Deze -cellen bevinden zich in de eilandjes 
van Langerhans in de pancreas. In een groot aantal 
studies zijn aanwijzingen gevonden voor een associatie 
van type 1 diabetes mellitus met enterovirussen, en in 
recente prospectieve studies wordt een etiologische rol 
in het ziekte proces verondersteld. Het is echter 
moeilijk om de bevindingen te extrapoleren naar een 
pathologisch mechanisme dat de oorzaak van -cel 
schade en het ontstaan van autoimmuniteit verklaart. in 
hoofdstuk 1 zijn verschillende mechanismen 
beschreven die zowel direct als indirect betrokken 
kunnen zijn bij de ontwikkeling van type 1 diabetes 
mellitus. In de eerste plaats is het mogelijk dat virussen 
-cel schade veroorzaken door hun cytopathisch effect 
op de cel. In een alternatief model is gepostuleerd dat 
een immunologische kruisreactie tussen het virale eiwit 
2C en het eiland antigeen glutamaat decarboxylase 
(GAD65) betrokken is bij de inductie van 
autoimmuniteit. Verder is verondersteld dat virale 
infecties een rol kunnen spelen in modulatie van het 
immuun systeem wat kan resulteren in het verlies van 
immnuologische tolerantie en activering van auto- 
reactieve T-cellen tegen eiland antigenen. In het 
onderzoek dat in dit proefschrift is beschreven, is 
geprobeerd aanwijzingen of bewijzen voor de 
verschillende mogelijke mechanismen van virus- 
geïnduceerde ß-cel schade te verkrijgen.
Op verschillende manieren is een associatie tussen 
enterovirussen en de ontwikkeling van type 1 diabetes 
mellitus aangetoond, en er lijkt een tijdsafhankelijke 
relatie te bestaan tussen het doormaken van een infectie 
en de ontwikkeling van auto-antistoffen tegen eilandjes 
waarvan GAD65 een belangrijk component is. De 
sequentie homologie tussen het enterovirale eiwit 2C 
en het -cel antigeen GAD65 vormde de basis voor de 
hypothese van moleculaire mimicry, een kruis- 
reagerende immuun respons gericht tegen deze 
antigenen. In type 1 diabetes mellitus is GAD65 een van 
de belangrijke en vroege auto-antigenen. Dit suggereert
dat moleculaire mimicry een relevant mechanisme kan 
zijn in de ontwikkeling van autoimmuniteit. In 
hoofdstuk 2 is aangetoond dat de 2C sequentie die 
homologie vertoond met GAD65, sterk geconserveerd is 
in de hele groep van coxsackie virus type B-achtige 
enterovirussen. De sterke mate van conservering van 
het PEVKEK motief in enterovirussen suggereert dat 
de mogelijkheid van moleculaire mimicry 
toegeschreven kan worden aan een hele groep van veel 
voorkomende virussen. Dit impliceert dat moleculaire 
mimicry een algemeen fenomeen zou zijn en 
gerestricteerd en/of gereguleerd wordt door andere 
(genetische) factoren. Naast de regulatie door 
‘’regulator cellen’‘ van het immuun systeem, is ook het 
HLA systeem betrokken bij moleculaire mimicry 
omdat het de presentatie van antigenen aan het 
immuunsysteem reguleert. HLA moleculen vormen de 
primaire genetische restrictie voor moleculaire 
mimicry. De mimicry peptiden afkomstig van 2C en 
GAD65, kunnen binden aan HLA-DR3 (hoofdstuk 2), 
Dit allel zou een rol kunnen spelen in de presentatie 
van peptides waartegen een T-cel kruisreactie kan 
ontstaan, met de ontwikkeling van autoimmuniteit als 
gevolg.
Naast onderzoek gericht op cellulaire kruis-reacties, is 
er ook onderzoek gedaan naar een mogelijke antistof 
kruis-reactie tegen de homologe sequentie van 2C en 
GAD65. In proefdier onderzoek is aangetoond dat 
antistoffen, geïnduceerd tegen p2C peptides kruis- 
reageren met GAD65. De relevantie in humane diabetes 
mellitus kon echter niet bewezen worden. In diabetes 
patiënten was geen correlatie tussen antistoffen tegen 
GAD65 en p2C gevonden. In hoofdstuk 3 is 
aangetoond dat antistoffen tegen het enterovirale p2C 
veel voor komen in de populatie, terwijl antistoffen 
tegen GAD65 specifiek zijn voor (pre-) diabetische 
patiënten. De hoge prevalentie van antistoffen tegen 
p2C suggereert dat deze antistoffen (in het algemeen) 
niet kruis-reageren met GAD65.
De mogelijkheid van directe pathogene effecten van 
enterovirussen in het proces van -cel destructie is 
bestudeerd door humane eilandjes van Langerhans in
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een kweeksysteem te infecteren met enterovirussen. In 
hoofdstuk 4 is beschreven dat infectie met CVB 
necrose van humane ß-cellen veroorzaakt in vitro. Een 
direct cytopathisch effect zou een rol kunnen spelen in 
patiënten met een acuut en snel verloop van de 
diabetes, maar verklaart niet de over het algemeen 
lange pre-klinische fase van de ziekte, waarin -cel 
schade toeneemt en auto-antistoffen tegen 
componenten van de eilandjes, en tegen GAD65 
waargenomen worden. Toch zouden ook lichte maar 
herhaalde infecties met -cel trope enterovirussen 
kunnen resulteren in een gradueel, maar cumulatief 
verlies aan -cellen, waarbij auto-antistoffen 
geïnduceerd worden als gevolg van de ß-cel schade. Dit 
proces zou leiden tot klinische manifestatie van de 
ziekte. Concluderend kan gesteld worden dat 
enterovirussen in staat zijn tot -cel schade via een 
direct, niet autoimmuun-gemedieerd, mechanisme.
In hoofdstuk 4 zijn verschillende mogelijk pathogene 
mechanismen van enterovirus-geïnduceerde diabetes 
onderzocht in een kind dat een acute vorm van diabetes 
mellitus ontwikkelde tijdens een ernstige infectie met 
ECHO virus type 9. In deze patiënt werd geen bewijs 
gevonden voor een direct cytopathisch effect van het 
virus op de -cellen. Verder werden geen kruis- 
reagerende T cel responsen tegen het virale eiwit 2C en 
het auto-antigeen GAD65 gevonden, hoewel het kind 
voldeed aan de genetische voorwaarde dat het een HLA 
type bevatte dat peptides afkomstig van de homologe 
eiwitten kan binden. De patiënt ontwikkelde ook geen 
antistoffen tegen GAD65. Het ontbreken van 
aanwijzingen voor een direct cytopathisch effect, of een 
indirect effect door moleculaire mimicry, 
veronderstelde de mogelijkheid van een ander indirect 
mechanisme, dat de betrokkenheid van enterovirussen 
in het ontstaan van diabetes kan verklaren.
Een infectie met een pancreatroop enterovirus en de 
bijkomende lokale ontstekingsreactie veroorzaakt 
weefsel schade. Tijdens infectie en ontsteking in de 
pancreas, kunnen signaal eiwitten, zogenaamde 
cytokinen worden geproduceerd door witte bloedcellen, 
die toxisch zijn voor de ß-cel. In hoofdstuk 5 is 
beschreven dat CVB een sterke TNF-a en IL-1ß 
respons veroorzaakt in witte bloedcellen cellen, die
betrokken zij bij een ontstekingsproces. Verder is 
bekend dat vele virussen in staat zijn tot modulatie van 
de immuunrespons door de immuunrespons in de 
richting van een Th1 type respons te dirigeren (IL-2, 
IFN- and TNF- productie), waarbij de Th2 type 
respons (IL-4 en IL-10 secretie) onderdrukt wordt. Een 
verschuiving van de immuunrespons richting Th1 
responsen is geassocieerd met een snelle ontwikkeling 
van diabetes. Wij hebben aangetoond dat blootstelling 
van geïsoleerde witte bloedcellen aan CVB resulteert in 
de productie van IL-2, IFN-y en IL-10, maar geen IL-4 
(hoofdstuk 5). De inductie van IL-2 en IFN-y en het 
gebrek aan IL-4 na CVB stimulatie zou mogelijk de 
immuunrespons in de richting van (auto-agressieve) 
Th1 responsen kunnen sturen. Verder is aangetoond dat 
expressie van IL-10 in de pancreas in NOD muizen, de 
ontwikkeling van diabetes versnelt, immunologische 
tolerantie doorbreekt, en weefsel-specifiek 
autoimmuniteit induceert. Dus blootstelling aan 
enterovirussen induceert de productie van cytokinen 
door immuun competente cellen, die kunnen bijdragen 
aan de ontwikkeling van autoimmuniteit.
In hoofdstuk 6 is aangetoond dat niet alleen 
immuuncompetente cellen aanleiding kunnen geven tot 
de productie van cytokinen, maar dat ook een infectie 
van ductale pancreas cellen met CVB4 resulteert in de 
productie van TNF- door de geïnfecteerde cellen. De 
ductaalcellen vormen de afvoerbuisjes van de exocriene 
pancreas naar de darmen en zijn dicht bij de eilandjes 
van Langerhans gesitueerd. De productie van TNF- 
kan volledig worden geremd door nicotinamide, een 
medicijn dat gebruikt wordt in klinische trials om de 
ontwikkeling van diabetes te vertragen en/of 
voorkomen. De precieze rol van TNF-x in de pancreas 
is nog niet vastgesteld. Er zijn echter sterke 
aanwijzingen dat TNF- betrokken is bij de 
ontwikkeling van type 1 diabetes mellitus.
In hoofdstuk 7 tenslotte, zijn de beschreven resultaten 
samengevat en bediscussieerd. Concluderend kan 
gesteld worden dat enterovirus infecties op 
verschillende wijzen en tijdens verschillende stadia van 
de ontwikkeling van type 1 diabetes mellitus kunnen 
bijdragen aan het verloop van de ziekte.
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